Altered motor phenotype and dopamine transmission associated with mutations of the parkinsonian gene LRRK2 by Longo, Francesco
   
 Università degli Studi di Ferrara
 
 
DOTTORATO DI RICERCA IN  
FARMACOLOGIA E ONCOLOGIA MOLECOLARE 
 
CICLO XXVII 
 
 
COORDINATORE Prof. Antonio Cuneo 
 
 
 
 
 
 
 
 
Altered motor phenotype and dopamine 
transmission associated with mutations of the 
parkinsonian gene LRRK2 
 
 
Settore Scientifico Disciplinare BIO/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dottorando                                                                             Tutore 
Dott. Longo Francesco                                                            Prof. Morari Michele 
 
 
 
 
 
 
 
 
 
 
 
Anni 2012/2014  
1 
 
SUMMARY 
 
 
 INTRODUCTION 4 
 LRRK2: a protein genetically implicated in Parkinson's Disease 5 
 Protein organization 5 
                        Dimerization and autophosphorylation 7 
 Mutation 8 
 Parkinson’s Disease and LRRK2-associated phenotype: the clinical 
scenario 
11 
 Parkinson’s Disease overview 11 
 Genetics of Parkinson’s Disease 13 
 LRRK2-associated phenotype 18 
 Neuropathology  of LRRK2 mutation carriers 19 
 LRRK2: protein interaction network and pathogenic mechanisms 21 
 Expression 21 
 Interaction network and cellular function 22 
 LRRK2: animal models 31 
 LRRK2 knockout models 32 
 LRRK2 transgenic models 32 
 AIM OF THE STUDY 35 
 METHODS 37 
 Subject 38 
 Behavioral analysis  38 
 Experimental design: longitudinal study (Part 1) 38 
 LRRK2 kinase inhibitor administration 39 
 Experimental design: study on dopaminergic transmission (Part 2) 39 
 Drug administration 40 
 Bar test 40 
 Drag test 40 
 Rotarod test 41 
 Spontaneous motor activity 41 
 In vivo microdialysis 41 
 Neurochemical analysis using LC-MS 42 
 Ex vivo studies 43 
2 
 
 Synaptosomes preparation 43 
 [
3
H]-WIN 35,428 saturation binding experiments 43 
 Dopamine Uptake Assay 43 
 In vivo PK study 44 
 Cell cultures and treatments 44 
 Cells and tissue lysis 45 
 Western blotting 45 
 Immunohistochemistry 45 
 Stereology and neuron counting  46 
 Data presentation and statistical analysis 46 
 Drugs 47 
 RESULTS 48 
 Part 1. Behavioral analysis of mice carrying mutations within the LRRK2 
kinase domain 
49 
 Characterization of motor phenotype in aging G2019S KI and WT mice 49 
 Characterization of motor phenotype in aging D1994S KD and WT mice 52 
 Pharmacological inhibition of the LRRK2 kinase activity  54 
 Effect of the LRRK2 kinase inhibitor H-1152 on motor phenotype  54 
 Effect of the LRRK2 kinase inhibitor H-1152 on LRRK2 phosphorylation at 
Ser935 
57 
 Effect of the LRRK2 kinase inhibitor Nov-LRRK2-11 on motor phenotype in 
LRRK2 G2019S KI and WT mice 
60 
 Effect of the LRRK2 kinase inhibitor Nov-LRRK2-11 on LRRK2 phosphorylation 
at Ser935 
62 
 Part 2. Pharmacological manipulation of dopaminergic transmission in 
G2019S KI mice 
 
65 
 Haloperidol 65 
 SCH23390 66 
 Pramipexole 67 
 Relationship between G2019S mutation and DA reuptake in phenotypic 
mice 
 
68 
 GBR-12783 68 
 GBR-12783 and Nov-LRRK2-11 69 
 Analysis on DAT and VMAT2 protein levels  70 
 Membrane DAT expression and function 71 
3 
 
 In vivo microdialysis  72 
 Nigrostriatal DA system 74 
 DISCUSSION 76 
 Concluding remarks 83 
 REFERENCES  85 
 ORIGINAL PAPERS 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
LRRK2: a protein implicated in Parkinson's Disease 
Protein organization 
The leucine-rich repeat kinase 2 (LRRK2, PARK8) gene on chromosome 12 contains 51 
exons and encodes a large multifunctional and multidomain protein containing 2527 amino 
acids. LRRK2 is a ubiquitous, mainly cytosolic, protein with a molecular weight of 
approximately 285 kDa, predominantly existing in a dimeric conformation in vivo with 
different points of interaction through each individual monomer (Greggio et al., 2008). 
According to sequence analysis, LRRK2 shows a central catalytic domain with GTPase 
and kinase activities. However, the N-terminal portion presents protein-protein interaction 
domains such as the armadillo (residues 180-660), ankyrin (residues 690-860) and the 
namesake leucine-rich repeats (LRRs; residues 985-1274) domains, whereas the C-
terminal terminus hosts the structural repeat motif WD40 (residues 2142-2498; Fig.1). 
 
 
Fig. 1. Schematic representation of LRRK2 protein linear structure. 
 
Catalytic domains. LRRK2 encodes two different enzymatic activities: kinase and GTPase. 
The central region of the protein includes the Ras of complex protein (ROC) GTPase 
protein domain with the adjacent C-terminal of Roc domain (COR) in conjunction with a 
kinase domain. Considering LRRK2 in the context of evolutionarily related protein 
kinases, LRRK2 originates from a different source and bears a quite different sequence 
from the origin (Marin, 2006; 2008). LRRK2 belongs to the TKL subfamily of human 
protein kinases (Manning et al., 2002), whose members show sequence similarity to both 
serine/threonine and tyrosine kinases. According to sequence similarity, its kinase domain 
shares homology with mixed-lineage kinases (MLKs) which are members of the mitogen 
activated protein kinase (MAPK) family (Jameel et al., 2009) However, more recent data  
indicate that the LRRK2 kinase domain mostly resembles the receptor-interacting protein 
kinase (RIPK) family (West et al., 2005), that plays a crucial role in cellular stress. The 
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presence of ROC and COR domains makes LRRK2 a member of a superfamily of proteins, 
named ROCO, that includes at least three other human proteins: LRRK1, DAPK1 and 
MASL1 (Marin, 2008). The human proteins LRRK2 and LRRK1 belong to a subgroup of 
ROCO proteins that always have an N-terminal LRR and a C-terminal kinase domain in 
addition to the ROC-COR tandem. This pair of domains is conserved throughout evolution, 
suggesting their functional interdependence. According to the model of the homologous 
domain in prokaryote C. tepidum, the COR domain (residues 1524-1837) is composed of 
nine α-helices and six β-sheets that are linked by a loop exposed to the solvent (Gotthardt 
et al., 2008). Interestingly, the prediction for human COR differs from the C. tepidum 
primarily in its C-terminal half, an area responsible for dimerization, thus suggesting that 
in human LRRK2, dimerization occurrs through its ROC domain. Indeed, the monomeric 
structure of the ROC domain (residues 1335-1515) comprises five α-helices and six β-
sheets that are linked by loops, and the dimer form is stabilized through hydrogen bindings 
and hydrophobic interactions. The surface of the dimer presents only one functional 
ligand-binding unit, showing unique nucleotide and Mg
2+
 binding sites with contributions 
from both monomers (Deng et al., 2008). In vitro studies have shown that LRRK2 can bind 
GTP through the GTPase domain via a phosphate-binding motif (P-loop) region, and that it 
can hydrolyze GTP involving a catalytic Switch II motif that is critical for GTPase activity. 
A high-resolution kinase domain model, recently obtained from the homolog ROCO4, has 
been proposed as a platform for understanding the human LRRK2 kinase domain (residues 
1183-2134) that is formed by seven α-helices and six β-sheets linked by loops, which are 
exposed to the solvent (Gilsbach et al., 2012). LRRK2 represents an unusual protein in 
which two distinct enzymatic domains within a single polypeptide chain interacts to 
regulate activity. In particular, the kinase activity is stimulated upon GTP binding to ROC, 
and it is reasonable to suppose that ROC regulates kinase activity by changing its 
conformations (active/inactive). Thus, a loss of GTP binding or an increased turnover of 
GTP to GDP should result in lowered kinase activity (Deng et al., 2008). Moreover, 
several studies demonstrated that LRRK2 self-regulation is a mechanism for controlling its 
kinase activity, which is mediated, in part, by its GTPase domain and homodimerization. 
Similar to MAPKKKs, which are regulated by small GTPases, LRRK2 kinase activity 
might be regulated by its own GTPase domain in an intrinsic manner (Lee et al., 2012a). 
Repeat domains. Various investigators have identified four domains composed of 
structural repeat motifs likely to be involved in regulation and localization of LRRK2. The 
presence of these particular domains occurring in 14% of all prokaryotic and eukariotic 
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proteins (Marcotte et al., 1999), suggests that LRRK2, in addition to its predicted protein 
kinase and GTPase activities, acts as a scaffold in different multiprotein signaling complex 
pathways. Although the presence of the armadillo repeats (ARM) domain in the N-
terminus of the protein has been questioned, recent studies concluded that LRRK2 contains 
ARM-like repeats domain. This domain is formed by 21 α-helices grouped to form 
supercoil, and are linked  by loops to form a curved structure (Cardona et al., 2014; Marin, 
2008). The following domain, in order from N- to C-terminus, is the ankyrin repeats 
(ANK) domain, found in diverse bacterial and eukaryotic proteins. It is compared to 
cytoskeletal erythrocyte ankyrin characterized by two antiparallel α-helices followed by a 
loop to form a gently curved structure. According to the various models proposed by 
different groups, the LRRs domain is located N-terminal to the ROC domain and is 
composed of 14 repeats. The first 13 repeats share the LRR consensus sequence found in 
LRR proteins interacting with Ras, whereas the 14th repeat deviates from this consensus. 
These 14 repeats are grouped into two modules and each LRR subunit contributes to form 
a curved β-sheets linked by a large loop (Cardona et al., 2014). 
Located at the C-terminal end of the protein, the predicted WD40 domain of LRRK2 
comprises seven repeats formed by 30 -sheets linked by loops to form a circular bladed 
propeller-like structure (Cardona et al., 2014). Although WD40 has been identified in 
many proteins with different functions as well as proteins involved in the cytoskeletal 
assembly, vesicle formation and trafficking, or in proteins with enzymatic activity, the 
structure of this domain is well conserved and represents the most common repeat domain 
found in the human protein. Different studies also demonstrated that WD40 is crucial for 
LRRK2 physiological and pathological activities, playing an important role in the synaptic 
vesicular network of LRRK2 (Piccoli et al., 2011).  
 
Dimerization and autophosphorylation 
Studies using ROCO proteins from lower organisms indicate that LRRK2 predominantly 
exists in a dimeric conformation, and  dimerization occurs in the ROC-COR bi-domain 
(Deng et al., 2008; Greggio et al., 2008), even though different other points of interaction 
through each individual monomer have been found. In particular, when the ROC domain 
was used as a bait in a yeast two-hybrid system, it bound to the N-terminus of LRRK2, the 
C-terminus of the LRR domain, the N-terminus of the ROC domain, and the C-terminus of 
the WD40 domain (Greggio et al., 2008). Interestingly, the deletion of the ROC domain is 
not sufficient to prevent dimerization, suggesting additional interaction regions within 
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LRRK2. Since a N-terminal deletion of the ANK and LRR domains does not reduce 
dimerization, whereas a WD40 truncated-LRRK2 could not dimerize, ROC and WD40 
domains seems to be critical for LRRK2 dimerization. Dimer formation is a common 
phenomenon among protein kinases and can help to mediate different auto-regulation and 
downstream signaling pathways. In addition, allosteric regulation is mediated by 
homodimerization in a number of serine-threonine kinases including mitogen-activated 
protein (MAP) kinases, p38, c-Jun N-terminal kinase (JNK), and their upstream kinases 
(Leung and Lassam, 2001; Ohren et al., 2004). Despite LRRK2 monomeric form is the 
predominant species in cells and might have kinase activity, experimental evidence 
suggests that LRRK2 exists and functions as a dimer with autophosphorylation of the full-
lenght protein occurring as an intramolecular (cis) event (Berger et al., 2010; Greggio et 
al., 2008). It was demonstrated that the autophosphorylation sites such as Thr1410, 
Thr1491 and Thr1503 are located mainly within the ROC domain (Gloeckner et al., 2010; 
Greggio et al., 2009; Kamikawaji et al., 2009; Pungaliya et al., 2010) where GTPase 
activity of LRRK2 is localized. In this scenario, autophosphorylation could represent an 
intramolecular post-translational modification that regulates the GTPase activity 
suggesting that the kinase activity acts as an internal modulator of the ROC domain and 
consequently of signal transmission. Moreover GTPase activity may be also be regulated 
through the recruitment of other cellular proteins (Gotthardt et al., 2008).  
 
Mutations 
The complete open reading frame of LRRK2 codes for a 2527 amino acid protein and as 
for many other large genes, a number of known variants can be found along the coding 
sequence. To date, more than 100 amino acid substitutions have been reported in human 
LRRK2 (Rubio et al., 2012), many of which are not currently linked to any disease. Some 
polymorphisms have been related to different pathologies such as leprosy (Zhang et al., 
2009) or cancer (Hassin-Baer et al., 2009) and, possibly, inflammatory bowel disease 
(Barrett et al., 2008), whereas others are linked to neurodegenerative disease or  represent 
an important risk factor (Paisan-Ruiz et al., 2013; Paisan-Ruiz et al., 2008). In 2004, two 
independent groups (Paisan-Ruiz et al., 2004; Zimprich et al., 2004) showed, for the first 
time, that mutations of LRRK2 were linked to dominantly inherited Parkinson’s disease 
(PD), corroborating a previous study which identified PARK8 as a new locus associated 
with PD within large Japanese family (Funayama et al., 2002). This initial discovery had a 
significant impact on the functional characterization of LRRK2, shedding light on disease-
causing mutations in this protein, and on the genetics of PD (Fig. 2).  
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Fig. 2. Distribution of the PD-related substitutions in relation to the functional domains of LRRK2. The mutations 
described as pathogenic are in red. 
 
Of note, six missense mutations that include the p.N1437H, p.R1441C/G/H, p.Y1699C, 
p.S1761R, p.G2019S, and p.I2020T substitutions, clearly segregate with disease and are 
clustered within the enzymatic core of the protein (Cookson, 2010; Mata et al., 2006). In 
particular, the substitution of a glycine with a serine in position 2019 (G2019S) is located 
in the activation loop of the kinase domain at the conserved Mg
2+
-binding motif 
(Goldwurm et al., 2005) and represents the most common PD-related mutation.  The 
G2019S substitution induces a stabilization of the enzyme in the active form leading to an 
increased kinase activity in vitro (Greggio et al., 2006; Jaleel et al., 2007; West et al., 
2005) and in vivo (Sheng et al., 2012). This mutation facilitates substrates access without 
an enhancement of substrate affinity (West et al., 2005). The other pathogenic mutation 
located within the kinase domain is represented by I2020T but how it affects protein 
function is still debated. Some studies reported that this mutation results in an increased 
kinase activity (Gloeckner et al., 2006; Kamikawaji et al., 2013), even though such 
increase is less marked than that caused by G2019S, while other groups revealed an 
unchanged  or a decreased function (Jaleel et al., 2007; Nichols et al., 2010). Furthermore, 
structure model analysis suggested that G2019S introduces a phosphorylation site (most 
mutations introduce a S or a T) or stabilizes an active form by hydrogen bonds, whereas 
the introduction of an extra hydrogen bond by I2020T could stabilize the inactive form of 
the kinase domain (Gilsbach et al., 2012). The second most common LRRK2 mutation, 
R1441C, together with two other variations of the same codon (R1441G and R1441H), has 
been found in the ROC/GTPase domain and is located at the interface of the ROC and 
COR domains (Lewis et al., 2007; Li et al., 2007). At the functional level, the R1441 
mutations causes an increase of the affinity of LRRK2 for GTP which results in a reduced 
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GTPase activity, and, as a consequence, in a decrease in GTP hydrolysis (Liao et al., 
2014). The ROC mutations lead to longer lasting activation of LRRK2 compared to the 
wild-type protein, due to the persistent GTP-bound form. However, the three mutations 
cause the loss of a positive charge (arginine) and affect the domain surface causing 
misfolding of ROC domain (Gotthardt et al., 2008). According to structure analysis, all 
three substitutions have an effect on protein stability, whereas only R1441C/G affects its 
function. In particular, the R1441H mutation induces an important effect on the tertiary 
structure of LRRK2 that impairs dimerization (Cardona et al., 2014). As for the R1441 
mutation, also the substitution of tyrosine with cytosine at the 1699 residue located on the 
outer surface of the COR domain leads to a reduction in GTPase activity via alteration of 
the ROC and COR domains interaction (Daniels et al., 2011). Outside of the 
ROC/COR/Kinase enzymatic core of LRRK2, several groups have shown different amino 
acid variants, although most of them do not show any association with PD (Cardona et al., 
2014). The identification of mutations within the WD40 and the LLR domains, together 
with the evidence that these domains are involved in protein-protein interactions, prompted 
several groups to analyze the role and the modifications occurring in these domains. At the 
C-terminus of the protein, the G2385R substitution lies on the surface of one of the 
propeller blades of the WD40 domain (Mata et al., 2006) and shows a clear genetic 
association with PD although its effects are controversial (Fung et al., 2006; Tan et al., 
2007). Some reports showed that G2385R decreases kinase activity both in vitro and in 
vivo (Jaleel et al., 2007; Rudenko et al., 2012)  whereas others did not find any significant 
difference compared to the wild-type protein (Nichols et al., 2010; West et al., 2007). 
However, it has recently been reported that the G2385R variant, which destabilizes 
LRRK2 structure, only has a mild impact on LRRK2 functional properties in the cell 
(Piccoli et al., 2011). On one hand, it increases the binding to Hsp90 (heat-shock protein of 
90 kDa) which plays a role in maintaining LRRK2 stability (Rudenko et al., 2012). On the 
other hand, it decreases LRRK2 ability to bind 14-3-3 proteins, a family of conserved 
regulatory molecules expressed in all eukaryotic cells, able to bind a multitude of 
functionally diverse signaling proteins, including kinases, phosphatases, and 
transmembrane receptors (Fu et al., 2000). A number of variants have also been described 
at the N-terminus of the protein. Although three different variants are located within the 
ARM domain, only one of them (E334K), affecting the electrostatic surface and charging 
distribution in this domain, has been described as a likely PD-associated mutation 
(Cardona et al., 2014). Potentially pathogenic variants have been described into the ANK 
domain. In particular, the R793M mutation, exposed on the surface of the helix 2 of the 
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putative ankyrine repeat 4, alters the structural integrity and, consequently, the protein-
protein interaction properties of LRRK2 (Mills et al., 2012). Inside the LLR repeats 
domain, four substitution (Q1111H, I1122V, I1192V and S1228T) are considered to be 
pathogenic. These amino acid substitutions, described by different groups, have been 
shown to alter the domain stability affecting the interaction with other proteins without 
altering protein function (Cardona et al., 2014). 
 
 
Parkinson’s Disease and LRRK2-associated phenotype: the clinical scenario  
 
Parkinson’s Disease overview  
In the last two decades there has been a substantial evolution of the classical view of the 
second most common progressive neurological disorder in aging populations. PD (OMIM 
168600) affects 1.5 % of the population over 60 years of age, with an incidence of 17–93 
in 100 000 individuals per year, rising with age (Lees, 2009).  
For many years, after James Parkinson’s clinical description of the shaking palsy in 1817, 
the presence of a genetic component of PD has been debated, until Polymeropoulos and 
colleagues (Polymeropoulos et al., 1997) identified, in 1997, a pathogenic missense 
mutation  in the α-synuclein gene (SNCA) of an Italian kindred where PD was inherited in 
autosomal-dominant fashion. This initial identification, followed by the finding that 
mutations in the same gene was associated with familial PD and work as a risk factor in 
sporadic PD as well (Cookson, 2010), had a significant impact on our understanding of the 
pathology. Indeed, the inherited and sporadic PD have common pathogenic mechanisms. 
Substantial evidence from postmortem human brains defined important neuropathological 
hallmarks of PD. Traditionally, PD has been considered a sporadic disorder pathologically 
characterized by the selective and progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) with consequent depletion of dopamine (DA) in 
striatum and in other projection areas. Moreover, in the surviving neurons, α-synuclein is 
the main component of filamentous assemblies termed Lewy bodies (LBs) and  Lewy 
neurites, where it accumulates in an aggregate form (Spillantini et al., 1997; Weintraub et 
al., 2008). Even though the mechanism behind LBs formation remains debated, further 
immunoreactivity studies have identified additional proteins such as ubiquitin, αB-
Crystallin, Hsp70, Hsp40 as key components of LBs (Auluck et al., 2002; Pountney et al., 
2005). Of note, recent evidence now suggests the possibility that α-synuclein acts as a 
prion-like protein for spreading PD, propagating from neuron to neuron (Olanow and 
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Brundin, 2013). Nonetheless, whether LBs are neurotoxic or represent a protective 
neuronal response is currently debated (Cookson, 2009; McNaught and Olanow, 2006).  
The typical clinical presentation of PD includes akinesia, bradykinesia, rigidity and resting 
tremor, which are related predominantly to the progressive neurodegeneration of DA cells. 
However, several studies have established that non-dopaminergic and non-motor 
symptoms are common, occurring across all stages of PD. Symptoms like hyposmia, 
constipation, depression, apathy, psychosis, cognition impairment and sleep disorders are 
sometimes present before diagnosis, and are often poorly recognized and inadequately 
treated, leading to severe disability, impaired quality of life, and shorter life expectancy 
(Chaudhuri and Schapira, 2009). A variety of different types of studies indicate that the 
onset of PD is so gradual that it is often difficult to pinpoint in an individual patient when 
the disease first emerges. The variable course of the disorder once the motor symptoms 
develop depends on the age at symptom onset, with an older age causing a more rapid 
disease course. Although Braak’s suggestion that the disease process may start peripherally 
and spread to the olfactory pathways has given support to the possibility that autonomic 
symptoms may be considered as clinical correlates of LBs deposition in these regions, 
when and where the neuropathological process begins remains debated (Gaig and Tolosa, 
2009). 
 
Clinical treatment. Despite the research in neuroprotection continues to grow, and many 
cellular targets are being investigated, the possibility to pharmacologically stop or slow the 
progression of neurodegeneration remains elusive. To date no proven neuroprotective 
treatment is available for PD, and clinical approach is mainly focused on DA replacement 
in order to ameliorate motor symptoms and  improve the quality of life and life expectancy 
(Goetz and Pal, 2014). Currently, L-DOPA represents the most effective symptomatic 
treatment of PD since its introduction over 40 years ago (Cotzias, 1969). Being a prodrug, 
L-DOPA is inactive until it crosses the blood-brain barrier (BBB), and is decarboxylated to 
DA by aromatic amino acid decarboxylase (AADC) in surviving nigrostriatal 
dopaminergic neuron and, in advanced disease stages, striatal serotonin terminals. Because 
L-DOPA can be metabolized to DA also in the periphery, leading to significant 
gastrointestinal adverse drug reactions, peripherally restrained AADC inhibitors, such as 
benserazide or carbidopa are combined to L-DOPA to prevent its peripheral breakdown 
(Fahn, 2008).  
Unfortunately, the response to L-DOPA changes with the progression of the disease and 
side-effects also emerge over time. As L-DOPA dosage increases over time, dyskinesias 
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(abnormal involuntary movements) and motor fluctuations become more common in 
patients within a few years of therapy (Fabbrini et al., 2007). Furthermore, no treatment for 
preventing or eliminating dyskinesias exists, and the mechanisms underlying this motor 
disturbance are still poorly understood. 
It is important to note that although L-DOPA  remains the gold standard of symptomatic 
therapy of PD, other pharmacological agents are currently used. Monotherapy with 
dopamine agonists, which directly stimulate DA receptors, represents the logical choice to 
rescue the impairment in DA transmission in early PD. In addition, non-ergolinic 
compound (i.e. pramipexole and ropinirole), together with catechol-O-methyl transferase 
(COMT) inhibitors and MAO-B inhibitors (that both inhibit DA metabolism) can also be 
used safely in more advanced phases of the disease, in conjunction with L-DOPA, to 
reduce motor fluctuations and dyskinesias (Rascol et al., 2005). When motor fluctuations 
and dyskinesia develop, or medical therapy fails to control symptoms adequately, surgical 
interventions for advanced PD represent a valid option (Weiss et al., 2010). These 
interventions include brain invasive procedures such as deep brain stimulation (DBS) of 
the subthalamics nucleus (STN) or globus pallidus internus (GPi), pallidotomy and 
thalamotomy (Nijhawan et al., 2009; Odekerken et al., 2013; Okun and Vitek, 2004).  
Recently, a number of “non-pharmacological” strategies have emerged as alternative 
therapeutic approaches for PD, although most of them did not develop beyond the 
preclinical stage (Kordower, 2015). Gene transfer using viral vectors can provide long-
term expression of therapeutic proteins in vivo. To date, different therapeutic approaches 
with  adeno-associated virus (AAV) or lentiviral vectors, were undertaken to promote 
neuroprotection (by delivery of the neurotrophic factor neurturin), to enhance conversion 
of L-DOPA to DA (by delivery of AADC), and to modulate basal ganglia activity (by 
delivery of glutamic acid decarboxylase)(Mittermeyer et al., 2012; Muramatsu, 2010; Palfi 
et al., 2014). Finally, emerging evidence that differential expression of endogenous 
regulatory small RNAs, known as microRNAs (miRNAs), might play key regulatory roles 
in neurodegeneration, provides new therapeutic targets, opening a new avenues in PD 
therapy (Harraz et al., 2011). 
 
Genetics of Parkinson’s Disease  
In the last two decades, using classic linkage analysis, genome-wide association studies 
and exome sequencing, 18 chromosomal loci (PARK1–18; Table 1) have been associated 
with familial PD (Lesage and Brice, 2012). To date, critical reviews argue that grouping 
different PD forms by pathology allow to better understand pathogenesis, nevertheless 
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most accepted classification show that gene variations causing PD are grouped in 2 
categories: dominantly and recessively inherited mutations.  
 
Autosomal dominant PD genes. Although mutations in LRRK2, represent the most 
common cause of autosomal dominant PD (up to 10% of all familial forms) (Bonifati, 
2014), at least three other genes (SNCA, VPS35, EIF4EG1) have been conclusively 
established to cause PD in the same autosomal dominant manner. The above mentioned α-
synuclein is a 14 kDa protein localized to presynaptic terminals, in the nucleus, in the 
cytosol, in the mitochondria-associated membrane and in the endoplasmic reticulum 
(Guardia-Laguarta et al., 2014). The normal function of α-synuclein remains poorly 
understood and the precise mechanisms by which it leads to toxicity and cell death are also 
unclear. Substantial evidence suggests that α-syn function is related to its capacity to 
interact directly with particularly highly curved membranes phospholipids such as vesicles, 
playing a role in vesicle trafficking during exocytosis (Snead and Eliezer, 2014). Mutations 
in the SNCA gene (PARK1 locus), oxidative stress and post-translational modifications 
lead α-synuclein to adopt an oligomeric and/or fibrillary conformation that induces toxicity 
through several mechanism. These species could  impair mitochondrial structure and 
complex activity (Devi et al., 2008), as well as disrupt ER-Golgi vesicular transport, which 
results in toxic ER stress and impairs the efficiency of some protein degradation 
mechanisms acting as negative regulator of DA release (Abeliovich et al., 2000).  
Recently, the identification of the D620N variation on the Vacuolar Protein Sorting 35 
(VPS35) gene has been shown to cause late-onset L-DOPA-responsive autosomal 
dominant parkinsonism which is reminiscent of sporadic PD (Trinh and Farrer, 2013). The 
frequency of mutation carriers is low and estimated to represent about 0.1% of the PD 
population. This gene encodes a subunit of the retromer system which mediates 
intracellular retrograde transport of endosomes to the trans-Golgi network (TGN). How 
mutant VPS35 causes PD is presently unknown, even though several lines of evidence 
indicate that mutant VPS35 may cause neurodegeneration via a gain-of-function 
mechanism with a dominant-negative effect on retromer assembly  (Trinh and Farrer, 
2013). In particular, Vps35 D620N mutants appear to disrupt the cargo sorting function of 
retromer, causing a deficit in retromer-dependent trafficking of CI-M6PR (cation-
independent mannose-6-phosphate Receptor) and its ligand cathepsin D, likely arising 
from the generation and redistribution of enlarged endosome compartments that retain 
retromer (Follett et al., 2014).  
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Traditional linkage methods have recently identified the R1205H mutation in the EIF4G1 
(eukaryotic translation initiation factor 4-gamma 1) gene as an infrequent cause of 
dominantly inherited PD, with an estimated frequency between 0.02–0.2% in the PD 
population (Chartier-Harlin et al., 2011). Of note, the eIF4G1 protein is regulated by 
phosphorylation of eIF4E-binding proteins (4E-BP) through the mammalian target of 
rapamycin (mTOR) pathway (Ramirez-Valle et al., 2008), and represents a multisubunit 
translation initiation complex involved in mRNA translation processes that regulates cell 
survival in response to stress (Chartier-Harlin et al., 2011). Interestingly, several lines of 
evidence point to a crucial involvement of the translation initiation process in PD. Indeed, 
it has been shown that LRRK2 interacts with eIF4E and directly phosphorylates 4E-BP at 
the postsynaptic site in vitro (Lee et al., 2012b). Furthermore the mTOR pathway and 4E-
BP phosphorylation are strictly linked to PD. Activation of 4E-BP by rapamycin, or its 
transgenic overexpression, prevent DA neuron loss in Drosophila models (Tain et al., 
2009) and are associated with L-DOPA-induced dyskinesia (Santini et al., 2009). Finally, 
in a very recent study, OA Ross and colleagues established a link between VPS35 and 
EIF4G1 in α-synuclein-related neurodegeneration using a yeast model (Ross et al., 2015). 
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Table 1. Summary of genes and loci associated with PD. 
Locus Gene Chromosomal location  Inheritance Type of parkinsonism 
PARK1/PARK4 SNCA 4q21 AD + risk LOPD/EOPD 
PARK2 Parkin 6q25-q27 AR EOPD 
PARK3 Unknown 2p13 AD LOPD 
PARK5 UCHL1 4p14 AD LOPD 
PARK6 PINK1 1p36 AR EOPD 
PARK7 DJ-1 1p36 AR EOPD 
PARK8 LRRK2 12q12 AD LOPD 
PARK9 ATP13 A2 1p26 AR EOPD 
PARK10 Unknown 1p32 Unknown LOPD 
PARK11 GIGYF2 2q37 AD LOPD 
PARK12 Unknown Xq21-25 X-linked LOPD 
PARK13 HTRA2 2p12 AD LOPD 
PARK14 PLA2G6 22q13 AR EOPD 
PARK15 FBXO7 22q12-q13 AR EOPD 
PARK16 Unknown 1q32 Risk LOPD 
PARK17 GAK 4p16 Risk LOPD 
PARK18 HLA 6p21 Risk LOPD 
- EIF4GI 3q27 AD LOPD 
- GBA Iq21 Risk LOPD 
- MAPT 17q21 Risk LOPD 
- BST1 4q15 Risk LOPD 
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; EOPD, early-onset PD; LOPD, late-onset PD 
 
Autosomal recessive PD genes. Mutations, including point mutations and large 
rearrangements, leading to deletions or multiplications, in each of the following three 
genes, Parkin (PARK2), PINK1 (PTEN induced putative kinase 1; PARK6) and DJ-1 
(PARK7) have been identified worldwide.  
Mutations in PARK2 alone account for almost 50% of early-onset familial recessive PD 
cases and are compatible with ∼15% of sporadic PD forms (Bonifati, 2014). Over a 
hundred mutations in PARK2 have been reported, which include homozygous or 
heterozygous point mutations but also deletions and duplications. The encoded protein, 
Parkin, belongs to the ubiquitin E3 ligases family and interacts with ubiquitin-conjugating 
enzymes (E2s) to catalyze the attachment of ubiquitin to protein targets (Shimura et al., 
2000), thus tagging these proteins for destruction by the proteasome. In addition, Parkin is 
involved in mitochondrial maintenance, and mutations within this gene might be associated 
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with changes of mitochondrial autophagy and neuronal dysfunction (Park et al., 2009). 
Patients carrying Parkin mutations present L-DOPA-responsive PD, frequently 
accompanied by motor fluctuations and dyskinesias that often develop early in the course 
of treatment (Periquet et al., 2001). However, rarely LBs have been detected, although 
neural loss in nigrostriatal pathway is usually severe, suggesting pathogenic differences 
between the autosomal recessive and the classical forms of PD. Nonetheless, the first 
patient with pathogenic PINK1 mutations and LBs-positive pathology was recently 
reported (Bonifati, 2014). 
 Mutations in the PINK1 and DJ-1 gene are less common, accounting for ∼1–8%, and 1–
2% of early-onset PD cases, respectively (Bonifati, 2014). The protein encoded by PINK1 
is located in the mitochondrial membranes and is involved in the mitochondrial response to 
cellular and oxidative stress (Valente et al., 2004a). It is clear that PINK1, by acting 
upstream of parkin, is involved in the elimination of damaged mitochondria, and might 
protect neurons against mitochondrial dysfunction and proteasome-induced apoptosis 
(Bonifati, 2014). The clinical phenotype is similar to that caused by mutations in Parkin, 
with a slow disease progression and rare additional psychiatric disturbances, particularly 
anxiety and depression (Valente et al., 2004b).  
Interestingly DJ-1 is also likely to be involved in mitochondrial physiology; in fact it 
represents a sensor for oxidative stress and may mediate neuroprotection. In the presence 
of oxidative stress, DJ-1 has been shown to translocate to the mitochondria and exert a 
protective effect (Canet-Aviles et al., 2004). In particular, the L166P mutation  leads to a 
less stable protein and to the reduction of antioxidative activity, implicating a loss-of-
function mechanism (Moore et al., 2003). Finally, similar to the other recessive PD forms, 
the clinical picture includes an early onset, good response to L-DOPA, and slow 
progression. By analysis of these genes, it has come most clearly that repair of damaged 
mitochondria represents a common physiological function, but how these proteins are 
involved is not yet clear. 
Of note, other more rare recessively inherited forms of PD have been identified. Mutations 
in the ATP13A2 (ATPase type 13A2), PLA2G6 (phospholipase A2, group VI) and FBXO7 
(F-box only protein 7) genes cause an atypical PD-associated phenotype that is 
distinguished from the other three aforementioned forms by an earlier (juvenile) onset, 
partial or less sustained response to L-DOPA, and atypical clinical features such as upper 
motor neuron signs, pyramidal signs, dystonia, supranuclear gaze palsy, myoclonus and 
cognitive decline (Bonifati, 2014). 
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LRRK2-associated phenotype 
The majority of clinical reports on LRRK2 PD patients consistently indicate that their 
clinical  phenotype is not distinguishable from the idiopathic form (Healy et al., 2008; 
Paisan-Ruiz, 2009). PD patients carrying LRRK2 pathogenic mutations have been 
identified in more than 40 populations worldwide. In addition, variable degrees of 
population-specificity have been shown, indicating that ethnicity is an important factor that 
influences diagnosis (Paisan-Ruiz, 2009). Notably, penetrance of LRRK2 mutations is 
almost complete and age-dependent, with an increase between 17% to 85% from 50 to 70 
years of age, and some G2019S mutation carriers exhibiting the disease after 80 years of 
age (San Luciano et al., 2010). The most frequent LRRK2 mutation, G2019S, shows 
incomplete penetrance and this might explain why this mutation is detectable in patients 
with familial PD but also in some with sporadic PD, suggesting that genetic and/or 
environmental factors may associate with LRRK2 to trigger dopaminergic 
neurodegeneration (Hulihan et al., 2008). This variant is frequent in PD patients from 
southern Europe, in particular in Portuguese (16%), Spanish and Italian populations. 
However, the highest incidence has been reported in Nord African Arabs (42%) and in 
Ashkenazi Jewish (28%) (Paisan-Ruiz et al., 2013). Moreover, G2019S  is associated with 
a specific haplotype present in all subjects, suggesting that the mutation was transmitted by 
a single ancient founder across European population (Kachergus et al., 2005). Given the 
high frequency of the G2019S mutation, the clinical phenotype of LRRK2 patients is 
mostly associated with this mutation. Several studies consider tremor as the initial and 
predominant symptom of LRRK2 carriers but, in a recent study, tremor incidence was 
lower in patients with G2019S PD than idiopathic PD (Trinh et al., 2014). Overall, the 
G2019S mutation is often associated with the classical motor triad characterized by 
bradykinesia, rigidity and asymmetrical tremor, by a good response to L-DOPA and a slow 
and benign disease progression (Paisan-Ruiz, 2009). In addition, postural instability and 
dystonia have been reported, although dystonia may only appear due to a complication of 
both medical and surgical treatment (Healy et al., 2008). The impact on the susceptibility 
to develop L-DOPA-induced dyskinesias (LID) is also debated: some groups found it to be 
more frequent in G2019S carriers than idiopathic PD (Lesage et al., 2008), whereas others 
showed no difference, even though the time elapsed from L-DOPA treatment onset to LID 
appearance was significant longer in LRRK2 compared to non-LRRK2 carriers (Healy et 
al., 2008). Compared to sporadic PD patients, LRRK2 carriers present a lower risk of 
cognitive decline and psychiatric features (Alcalay et al., 2010); on the other hand, higher 
frequency of depression, anxiety and irritability have been reported. Interestingly, Shanker 
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and colleagues reported a trend for a greater risk of premorbid mood disorders in LRRK2 
patients compared to gene-negative patients, assuming that mood disorder susceptibility 
genes may modify LRRK2 mutation penetrance. Of note, numerous reports identified 
different degrees of cognitive alterations in a number of healthy asymptomatic G2019S 
carriers that could represent a hopeful way to investigate early markers for pre-
symptomatic PD (Thaler et al., 2012).  
The distribution in age at onset and the clinical features are similar in LRRK2 R1441C 
patients and idiopathic or LRRK2 G2019S PD patients. Moreover G2385R carrier patients 
demonstrate clinical features similar to non-carrier patients, indicating that mutations in 
different LRRK2 domains lead to similar clinical phenotypes. Lastly, patients carrying the 
Y1699C mutation show unilateral leg tremors at onset, foot dystonia and then 
bradykinesia, rigidity, and postural instability with good responsitivity to L-DOPA 
(Haugarvoll et al., 2008). 
 
Neuropathology  of LRRK2 mutation carriers 
The pathological features of patients with LRRK2 mutations are strikingly heterogeneous. 
Postmortem analysis from more than 30 LRRK2 mutation carriers displayed dopaminergic 
neuronal loss and gliosis in the SN, although  the same mutations can cause quite different 
neuropathology, and LBs or Lewy neurites are not present in all cases (Wider et al., 2010). 
The G2019S phenotype is often characterized by the presence of α-synuclein–immune-
positive LBs and, although other postmortem findings, such as tau-positive or ubiquitin-
immunoreactive inclusions, have been found, this mutation does not always manifest as 
synucleinopathy or LBs disease (Ruffmann et al., 2012). Rather than distinct processes, 
these pathological endpoints may share the same primary cause, assuming that LRRK2 and 
tau/ α -synuclein crosstalk along a common neurotoxicity pathway (Rajput et al., 2006). 
However, the exact relationship between α–synuclein and LRRK2 is unclear as 
postmortem localization studies have produced conflicting results (Sharma et al., 2011). 
Due to the growing interest in the potential interaction of these proteins in the pathogenesis 
of PD, a very recent study from Guerreiro group, using diverse and more rigorous 
techniques, showed that endogenous LRRK2 and α-synuclein interact in cells, mouse and 
human brain tissue. Their data show that the G2019S mutation does not alter the ability of 
LRRK2 to interact with α-synuclein in HEK-293 cells, indicating that the kinase domain, 
and hence the phosphorylation capacity of LRRK2, does not play a major role in its 
interaction with α-synuclein (Guerreiro et al., 2013). Interestingly, in cell models, an 
increase in LRRK2 expression is associated with elevation of α-synuclein mRNA 
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(Carballo-Carbajal et al., 2010). These features are consistent with reports that the levels of 
LRRK2, rather than its mutations, regulate the progression of neuropathology induced by 
PD-related α-synuclein mutants (Lin et al., 2009). Furthermore, despite the poor specificity 
of the different LRRK2 antibodies (Davies et al., 2013), a number of studies in human 
brain tissues showed the co-localization of LRRK2 with α-synuclein-immunoreactive LBs 
(Guerreiro et al., 2013),. Of note, analysis of LRRK2 mRNA expression in post-mortem 
brain tissue from control, idiopathic PD (IPD) cases and G2019S-positive PD cases 
showed, in addition to a widespread neuronal localization and weak levels in SN, 
significant reductions in non-nigral regions (cerebellum, amygdala, frontal cortex and 
cingulate gyrus) of IPD brain (Sharma et al., 2011). In this scenario, further work is 
required to explain the contrast between the increased levels of LRRK2 in PD brain 
regions with pathological accumulation of α-synuclein and the pathogenic role of LRRK2 
outside nigral neurons.   
The most striking variability was observed in R1441 mutation carriers. DA neuron loss and 
gliosis in the SN, without α-synuclein-positive inclusions, have been reported in the only 
case examined with the R1441G substitution (Marti-Masso et al., 2009), even though some 
autopsies from R1441C carriers showed various neuropathological patterns. Indeed, data 
from four patients revealed that one case did not show synuclein and tau pathology, two 
cases had LBs and Lewy’s neurites (LNs), and the remaining one showed neurofibrillary 
tangles (NFT) without either LBs or LNs (Wszolek et al., 1997). However, no pathology 
reports are available for p.R1441H substitution carriers. Finally, similar finding have been 
reported for the I2020T and Y1699C mutations that showed tau, LBs and ubiquitin-
positive cytoplasmic and nuclear inclusions (Ujiie et al., 2012). 
Understanding the mechanisms that lead to dopaminergic loss in LRRK2 patients 
represents the unresolved challenge in the LRRK2 field. The clinical and pathological 
heterogeneity of LRRK2 mutation carriers, together with the widespread expression of 
LRRK2, supported the idea that this protein interacts with other molecules in the affected 
neuronal populations, and this may play an important role in the accumulation and 
aggregation of unfolded proteins. As extensively suggested, LRRK2 interacts with other 
proteins which also form protein complexes (Cookson, 2010; Greggio et al., 2011), likely 
acting upstream of them. Moreover, additional genetic and environmental risk factors 
determine the type of pathology that develops in a given individual. For example, mutation 
of the genes encoding α-synuclein and tau, SNCA and microtubule associated protein tau 
(MAPT) respectively, could be the obvious candidate to influence pathogenesis, directly or 
indirectly interacting with the protein LRRK2. Likewise, different environmental factors 
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such as pesticides and head trauma might lead LRRK2 either towards tau or α-synuclein 
pathology (Li et al., 2014). To date, the physiological and pathophysiological 
consequences of LRRK2 mutation remain largely unknown. Investigators have largely 
attempted to validate LRRK2 protein interactors by using a LRRK2- dependent 
phosphorylation readout, but until now all attempts have failed. 
 
 
LRRK2: protein interaction network and pathogenic mechanisms  
  
Expression  
LRRK2 is found at high levels in several organs, such as liver, lung, kidney, heart, spleen, 
intestine and lymph nodes (Galter et al., 2006; Giasson et al., 2006; Hakimi et al., 2011), 
while is poorly expressed in the mammalian brain relative to most well-characterized 
protein kinases. Despite the lack of sensitive and specific antibodies (Davies et al., 2013), 
the neuroanatomical localization of LRRK2 in the brain showed a striking relation between 
LRRK2 gene expression and the nigrostriatal DA system affected in PD. In situ 
hybridization studies on LRRK2 mRNA in the mouse brain revealed that expression is 
highest in the cortex, moderate in striatum, olfactory tubercle, hippocampus and 
cerebellum, and lowest in SNpc (Biskup et al., 2006; Melrose et al., 2006). 
Within the brain, LRRK2 is abundantly expressed in neurons, but it can also be detected at 
lower levels in astrocytes and microglia where its expression can be induced by 
inflammatory stimuli (Giesert et al., 2013; Paisan-Ruiz, 2009). In the cortex, striatum, and 
SNpc, the pattern of LRRK2 expression differs within distinct neuronal subpopulations . 
Throughout the striatum, in both rats and mice, LRRK2 expression appeared to be 
restricted to medium spiny neurons, with low to undetectable expression in larger 
interneurons. This is also confirmed by the overlapping of DARPP-32 and LRRK2 staining 
in neuronal perikarya. In the last years, the expression of LRRK2 in SNpc has been object 
of intensive studies. Diverse studies failed to detected protein levels, while others, after 
having developed more specific anti-LRRK2 polyclonal antibodies, described LRRK2 
protein expression in the mouse and human SNpc, (Biskup et al., 2006; Greggio et al., 
2006; Melrose et al., 2007). Interestingly, although any LRRK2 signal using similar 
staining conditions has been found in rat SNpc dopaminergic neurons, minimal LRRK2-
immunoreactivity has been showed in the substantia nigra pars reticulata (SNpr) in both 
rats and mice (West et al., 2014). At a subcellular level, in striatal and cortical neurons, 
LRRK2 is localized throughout the cytoplasm of neuronal perikarya and dendritic 
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processes where it is associated with vesicular and intracellular membranous structures 
(i.e. mitochondria, endosomes, lysosomes, multivesicular bodies, lipid rafts, microtubule-
associated transport vesicles, synaptosomes, Golgi complex, and endoplasmic reticulum), 
with the microtubule network and other membrane-bound organelles (Alegre-Abarrategui 
et al., 2009; Biskup et al., 2006). The synaptic localization of LRRK2 represents a 
contentious issue. In particular, some studies found that LRRK2 expression does not 
overlap with presynaptic markers, including synaptotagmin-1 (a large protein able to bind 
Ca2+ and involved in the presynaptic vesicle membrane fusion) in striatal and cortical 
neurons, but has close association with TH-positive projections, suggesting a 
predominantly postsynaptic localization in the striatum (West et al., 2014). Instead, others 
investigators suggest that the association of LRRK2 with cytoskeletal elements hints a 
possible role in vesicular transport, protein trafficking and presynaptic vesicle 
endo/exocytosis (Belluzzi et al., 2012) as well as in membrane and protein turnover, 
including the lysosomal degradation pathway. The LRRK2 association with outer 
mitochondrial membrane in rodents may suggest a causal role in PD, where mitochondrial 
function is impaired. Interestingly, mitochondria undergo frequent fission and fusion 
events especially before a cell undergoes apoptosis, and these processes are regulated by 
molecular machinery that includes dynamin-related GTPases and WD40 repeat-containing 
proteins. Therefore, LRRK2 might potentially serve as a scaffold during mitochondrial 
fission and fusion (Li and Beal, 2005). 
 
Interaction network and cellular function 
LRRK2 protein distribution within various cell compartments might reflect a functional 
role in multiple cellular pathways (Fig.3). The physiological cellular function of LRRK2 is 
not clear despite strong evolutionary conservation of this class of protein. Some evidence 
suggests a role in cytoskeleton organization, translation regulation, autophagy-lysosomal 
pathways, neurite outgrowth, vesicular trafficking, neurotransmitter release and 
immunoregulation, but as mentioned above, little is known about the physiological 
interactors and/or regulators of LRRK2, and a few substrates for its domains have been 
described.  
23 
 
 
Fig. 3. LRRK2 involvement in cellular mechanisms. 
 
Cytoskeletal regulation. Ultrastructural analysis supports LRRK2 interaction with 
cytoskeletal proteins including tubulin, tubulin-associated tau and actin. A very recent 
study, in line with previous evidence, demonstrated a specific, direct interaction of LRRK2 
with three different β-tubulin isoforms, which is mediated by the LRRK2 ROC domain and 
the β-tubulin C-terminus. This interaction is dependent on guanidine nucleotide binding 
and modulated by ROC domain autophosphorylation. The R1441G mutation seems to 
disrupt this interaction, possibly by affecting tubulin acetylation. Conversely, embryonic 
fibroblasts (MEFs) obtained from LRRK2 knock-out mice show increased tubulin 
acetylation. Interestingly, Gillardon and collaborators found that recombinant human 
LRRK2 phosphorylates β-tubulin, and phosphorylation levels are three-fold enhanced in 
the presence of the G2019S mutation, with the consequential increase of microtubule 
polymerization (Gillardon, 2009). In addition, LRRK2 co-localizes with highly dynamic 
cytoskeletal structures in dopaminergic cells, and LRRK2 overexpression and mutation 
impact upon the morphology of growth cones (Law et al., 2014).  
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Moesin, a component of the ERM (ezrin/radixin/ moesin) family has been identified as one 
of the cytoskeletal LRRK2 kinase target (Parisiadou et al., 2009). These proteins play an 
important role in the regulation of the membrane structure and its organization by 
anchoring the actin cytoskeleton to the plasma membrane. Although moesin is likely to be 
only an efficient in vitro substrate for LRRK2, it allows the development of efficient model 
substrate peptides, called LRRKtide and Nictide, derived from ERK sequence, which 
helped improve the analysis of LRRK2 kinase activity in vitro (Jaleel et al., 2007). 
However, LRRK2 also plays a role in actin dynamics, interacting with actin isoforms and 
with the actin-associated proteins that contribute to filament assembly, organization and 
maintenance. A number of studies show that LRRK2 mutations lead to the accumulation of 
polymerized actin as well as phosphorylated ERM, and that these effects are reversed in 
LRRK2 knockout neurons (Parisiadou et al., 2009). Pathogenic mutations influence the 
interaction between LRRK2 and microtubules: some studies indicate that G2019S and 
R1441G/H  reduce LRRK2- β-tubulin interaction (Law et al., 2014), while others an 
increased affinity (Kett et al., 2012). Taken together, these data suggest a role for LRRK2 
in the regulation of cytoskeletal dynamics with implications for the pathogenesis of PD.  
Furthermore, the suggestion that LRRK2 can directly phosphorylate tubulin-associated tau 
is corroborated from the evidence that tau phosphorylation is reduced in LRRK2 knock-out 
mice (Kawakami et al., 2012). In addition, the G2019S and I2020T mutations increase tau-
phosphorylation, influencing the tau’s affinity for microtubules protein and promoting its 
aggregation (Melrose et al., 2010).  
 
Protein regulation and Autophagy. LRRK2 has been proposed to physically interact with 
14-3-3 proteins, upon phosphorylation at residues S910 and S935 at the N-terminus of the 
leucine-rich repeats (Dzamko et al., 2010; Nichols et al., 2010). The 14-3-3 proteins 
represent a family of conserved regulatory molecules that  usually assemble into either 
homo- or heterodimers and, in their dimeric form, bind to two phosphorylated residues 
which can come from the same target protein, or from two separate binding partners. These 
proteins have the ability to protect important regulatory sites from dephosphorylation, or to 
mediate dimerization of two distinct target proteins. Dzamko and colleagues showed that 
pathogenic LRRK2 mutations disrupt the binding between 14-3-3 and LRRK2: as a 
consequence, LRRK2 levels are decreased and LRKK2 is accumulated in non-cytosolic 
pools. How 14-3-3 interaction influences LRRK2 function or its cytoplasmic localization 
has not been clarified yet. It has been shown that this interaction does not control LRRK2 
protein kinase activity, as mutations of Ser910 and/or Ser935 do not influence LRRK2 
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catalytic activity or dimer formation of wild type LRRK2. However, Ser910/Ser935 
phosphorylation and 14-3-3 binding is markedly reduced in mouse tissues derived from 
homozygous R1441C knock-in mice that display impaired dopaminergic 
neurotransmission (Dzamko et al., 2010; Nichols et al., 2010; Tong et al., 2009). A very 
recent study describes an additional residue in the ROC domain involved in the regulation 
of the 14-3-3 binding to LRRK2. Binding of phospho-Ser1444 residue to 14-3-3 impairs 
LRRK2 kinase activity, and phosphorylation is abolished by pathogenic mutations in the 
ROC domain, even though whether this results in altered cytosolic localization of LRRK2 
has not been determined yet (Muda et al., 2014). In addition, the Ser910, Ser935 and 
Ser1444 residues are not phosphorylated by LRRK2 itself, but rather by multiple kinases, 
including cAMP-dependent protein kinase (PKA). This kinase is one of key regulators in 
signal transduction in the brain; it is activated in response to increasing concentrations of 
cAMP and phosphorylates a vast number of protein kinases, including the MAPKKK c-
Raf. Furthermore, PKA facilitates synaptic transmission and assumes an important 
function as a regulator of DA synthesis. In this context, LRRK2 kinase activity could be 
modulated by PKA-mediated binding of 14-3-3, suggesting that PKA acts as an upstream 
kinase for LRRK2 (Muda et al., 2014).  
Interaction between the LRRK2 ROC-COR domain with the DVL (dishevelled) 
phosphoproteins family (DVL1-3) has been reported. DVLs represent key regulators of 
Wnt (Wingless/Int) signalling pathway, which is  important for axon guidance, synapse 
formation and neuronal maintenance. Indeed, they can mediate the activation of small 
GTPases with structural similarity to the LRRK2 ROC domain. In this context, DVLs may 
influence LRRK2 GTPase activity, and ROC-COR domain mutations modulating LRRK2-
DVL interactions indirectly influence kinase activity (Sancho et al., 2009). In addition, 
LRRK2 has been reported to interact with various small GTPases including Rac1 (Chan et 
al., 2011), rab5b (Shin et al., 2008), and rab7 (Dodson et al., 2012). 
Accumulating evidence suggests that LRRK2 interacts with heat shock protein 90 (Hsp90) 
in vitro and in vivo, and that inhibition of Hsp90 disrupts this association, followed by 
LRRK2 degradation and increased cell viability. Hsp90 is a molecular chaperone essential 
for activating many signaling proteins and for regulating their stability in the eukaryotic 
cell. Moreover, Hsp90 contributes to the stabilization, activation, and/or translocation of 
client protein kinases, such as Src family tyrosine kinase and serine/threonine protein 
kinases, such as LRRK2. The binding of Hsp90 to LRRK2 seems to reflect protein 
instability, indeed the inhibition of Hsp90 chaperone function dramatically decreases the 
stability of LRRK2 in cell lines and primary neuronal cultures via a proteasome-mediated 
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degradation mechanism. Hsp90 could be a target for suppressing the accumulation of PD-
related LRRK2 mutants and their pathogenic activity  in neurons. Indeed, treatment of 
neurons with a Hsp90 inhibitor rescued the axon growth retardation defect caused by 
overexpression of the LRRK2 G2019S mutation (Wang et al., 2008). Furthermore, Hsp90 
shows greater affinity for G2385R LRRK2 than the wild-type form, and its inhibition leads 
to the association of mutant LRRK2 with high molecular mass native fractions, that 
probably represent proteasome degradation products. Of note the G2385R mutation within 
the WD40 domain, which represents a risk factor of PD, causes a partial loss ofkinase 
activity by reducing phosphorylation at Ser910/Ser935 sites, and a concomitant diminished 
ability to bind 14-3-3 proteins (Rudenko et al., 2012).  
Moreover, LRRK2 was found to interact with the C-terminus of Hsp70-interacting protein 
(CHIP), an E3 ubiquitin ligase that significantly reduces the cellular levels of LRRK2 by 
ubiquitination and proteasome-dependent degradation, leading to lowered LRRK2 protein 
levels (Ding and Goldberg, 2009). Binding to LRRK2 occurs between  the charged domain 
and the ROC domain of LRRK2, or between  the TPR domain of CHIP and the N-terminal 
region of LRRK2.Since the TPR domain of CHIP is well-known to bind to Hsp90, it is 
likely that a portion of the LRRK2-Hsp90 complex will also be associated with CHIP. 
Interestingly, because it has been reported that LRRK2 binds to the E3 ubiquitin ligase 
Parkin, enhancing its auto-ubiquitination activity, and that CHIP also forms a complex 
with Parkin enhancing its ubiquitin ligase activity, it is possible that the reported 
interaction between LRRK2 and Parkin is mediated by CHIP (Ding and Goldberg, 2009). It 
has been proposed that the ability of CHIP to degrade potentially neurotoxic misfolded, 
damaged or mutated proteins might diminish with age. In this contest diminished CHIP-
mediated degradation of LRRK2 in aged or stressed neurons may contribute to sporadic 
PD as well as familial PD in patients bearing LRRK2 mutations. 
In either case, current data indicate that LRRK2 protein levels nicely correlate with 
neuronal toxicity. The interaction with Hsp70 targets LRRK2 to the lysosomal membrane 
for chaperone-mediated degradation thus representing a mechanism to control protein 
levels, (Skibinski et al., 2014). Recently, Beilina and colleagues, using protein–protein 
interaction arrays, identified BCL2-associated athanogene 5, Rab7L1 (RAB7, member 
RAS oncogene family-like 1), and Cyclin-G–associated kinase, as binding partners of 
LRRK2. These proteins form a complex that promotes clearance of Golgi-derived vesicles 
through the autophagy–lysosome system both in vitro and in vivo, although the impact of 
these interactions on LRRK2 levels and chaperone-mediated autophagy remains unknown 
(Beilina et al., 2014). Interestingly, additional studies have investigated the interaction 
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between LRRK2 and mitogen-activated kinases (MAPKs), such as extracellular signal-
regulated kinase (ERK), Jun N-terminal kinase (JNK) and p38. LRRK2 induces the 
phosphorylation of MAPK/ERK kinases (MEK), while the G2019S mutation promotes 
autophagy in cells via the MEK/ERK pathway (Liou et al., 2008). 
 
Effect on protein translation. Evidence has been provided that LRRK2 is involved in one 
of the many established signaling cascades, including the mTOR and ERK pathway, and 
protein translation in general has been suggested to be instrumental to LRRK2 effects in 
fly models. In particular, both human LRRK2 and the Drosophila orthologue of LRRK2 
phosphorylate eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP), a negative 
regulator of eIF4E-mediated protein translation and a key mediator of various stress 
responses. 4E-BP is a target of mammalian target of rapamycin (mTOR), which is of 
interest in research on aging since recent evidence suggests that in diverse species, deletion 
of mTOR signalling components or treatment with the mTOR inhibitor, rapamycin, can 
extend lifespan. It has long been recognized that a key regulator of eIF4E function is the 
phosphorylation-induced release of 4E-BP from eIF4E. Although LRRK2 stimulates 
eIF4E-mediated protein translation both in vivo and in vitro, it attenuates resistance to 
oxidative stress and survival of DA neurons in Drosophila. The chronic inactivation of 4E-
BP by pathogenic LRRK2 mutations might lead to deregulation of protein translation, 
likely resulting in age-dependent loss of DA neurons (Imai et al., 2008). mTOR signaling 
may link LRRK2 with aging, despite the fact that experiments have shown that 4E-BP is a 
relatively poor substrate for highly purified LRRK2. 
Because recent genome-wide association studies (GWAS) revealed that the LRRK2 locus 
represents a genetic risk factor for sporadic PD (Satake et al., 2009), the potential alteration 
of LRRK2 expression in the etiology of sporadic PD is of outmost interest. To this purpose 
a number of studies have highlighted a role for LRRK2 in microRNA (miRNA) regulation. 
miRNAs are evolutionarily conserved small non-protein-coding transcripts that bind to 
partially complementary sites in the 3′-untranslated region (3′-UTR) of target messenger 
RNAs (mRNAs), and thereby control the translation of their target gene. A number of 
miRNAs have been associated with neuronal development, synaptic plasticity, memory 
formation and neurodegenerative diseases in the nervous system through their regulation of 
the translation of targeted genes (Hebert and De Strooper, 2009). Cho and colleagues, 
reported that the levels of LRRK2 were enhanced whereas those of miRNA-205 (miR-205) 
were decreased in the frontal cortex of sporadic PD patients (Cho et al., 2013). Since 
LRRK2 mRNA levels (i.e. LRRK2 expression) remained unchanged, a potential post-
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transcriptional modification of the LRRK2 protein expression in the sporadic PD brain was 
suggested. Interestingly, miR-205 reduced LRRK2 levels in cell lines and primary neuron 
cultures, through targeting its binding site in the 3′-UTR of LRRK2 gene. In addition, 
introduction of miR-205 prevented the neurite outgrowth defects in the neurons expressing 
a PD-related LRRK2 R1441G mutant. In this context, the downregulation of miR-205 may 
play a role in the pathogenic elevation of LRRK2 protein in the sporadic PD brain (Cho et 
al., 2013). These findings support previous data in which LRRK2, through its kinase 
domain, was shown to control the production and the regulation of let-7 and miR-184,  
(Gehrke et al., 2010). Unfortunately, at this stage little is known about the alteration in 
LRRK2 function during the aging process, and no specific post-translational modifications 
associated with aging are known, as it is undetermined how people carrying LRRK2 
mutations develop disease as adults.  
 
Relationship to mitochondria. Mitochondrial dysfunction is widely recognized as a trigger 
of PD, and LRRK2 has been found to be involved in different mitochondrial events, 
including mitochondrial dynamics and morphology, mitochondrial calcium buffering, ROS 
production and mitochondrial membrane potential maintenance. In vitro studies on primary 
cultures of cortical neurons found that LRRK2 colocalizes with the mitochondrial marker 
Cyto C and partially with the fission Dynamin like protein 1 (DLP1). Interestingly, 
LRRK2 G2019S overexpression in cortical neurons increases DLP-1 activity and promotes 
mitochondrial fission, suggesting that LRRK2 is likely to be involved in mitochondrial 
fission/fusion dynamics (Niu et al., 2012). In addition, cellular transfection with LRRK2 
WT and LRRK2 G2019S could induce mitochondrial fragmentation and consequent cell 
death (Iaccarino et al., 2007). A reduction of mitochondrial membrane potential and  
intracellular ATP levels, accompanied by mitochondrial elongation, have been reported in 
skin biopsies from  human LRRK2 G2019S carriers (Mortiboys et al., 2010). This is in 
accordance with the study of Papkovskaia and colleagues (Papkovskaia et al., 2012) that 
pointed to a kinase-dependent mechanism. Moreover, LRRK2 mutants are involved in the 
modulation of the peroxiredoxin3 activity. This enzyme, located within mitochondria, acts 
as antioxidant and is phosphorylated by LRRK2 (Angeles et al., 2011). Reduced cell 
survival and mitochondrial dysfunction, such as increased sensitivity to rotenone-mediated 
complex I inhibition (Ng et al., 2009), have been also shown in Drosophila flies carrying 
LRRK2 mutants, whereas WT LRRK2, seems to attenuate H2O2-induced oxidative stress, 
suggesting a protective role for LRRK2 (Liou et al., 2008). Mutations in LRRK2 could 
affect mitochondrial function by increasing the vulnerability to oxidative stress. Induced 
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pluripotent stem cells (iPSCs) derived from fibroblast of G2019S LRRK2 carriers show 
higher levels of mitochondrial DNA (mtDNA) damage than cells from control subjects, 
and are characterized by a reduced mitochondrial respiration and motility (Papkovskaia et 
al., 2012). 
 
LRRK2 and vesicle trafficking. Given the synaptic expression of LRRK2 and its 
association with the membranous structures involved in vesicular release, including 
endoplasmic reticulum, Golgi apparatus, cytoskeleton, lipid raft and synaptic vesicles 
(Migheli et al., 2013), it is not surprising that LRRK2 is involved in vesicle trafficking and 
neurotransmitter release (Tong et al., 2009). Of note, the activated form of LRRK2 
(LRRK2 dimer) is substantially enriched at the membrane of cells expressing endogenous 
or exogenous LRRK2, and the membrane-associated fraction of LRRK2 possesses greater 
kinase activity than cytosolic LRRK2, suggesting intense catalytic role at this site (Berger 
et al., 2010). Several studies show that LRRK2 acts at the synaptic site, interacting with a 
high number of pre-synaptic proteins including NSF (N-ethylmaleimide-sensitive fusion 
factor), AP-2 (adapter protein 2), SV2A (synapticvescicle protein 2A), synapsin 1A, 
syntaxin 1, clathrin (Piccoli et al., 2011), Rab5 and actin (Meixner et al., 2011). Shin and 
colleagues reported that the interaction between LRRK2 and Rab5 is involved in the 
modulation of synaptic vesicle endocytosis (Shin et al., 2008). Recently in vivo and in 
vitro studies revealed the interaction between LRRK2 and ArfGAP1 (ADP-ribosylation 
factor GTPase-activating protein 1). ArfGAP1 is able to promote the GTPase activity of 
Arf1 (ADP-ribosylation factor 1), a small protein involved in maintaining the morphology 
of the Golgi apparatus and the extrusion of vesicular proteins to the endoplasmic reticulum 
(Donaldson and Radhakrishna, 2001).  
LRRK2 interacts with actin filaments and microtubules involved in vesicular transport and 
trafficking, regulating ERM phosphorylation via kinase activity and actin polymerization 
(Parisiadou et al., 2009). Interestingly, Cirnaru and coworkers (Cirnaru et al., 2014) 
showed a reduction of the interaction between LRRK2 and synaptic vesicles and a 
simultaneous enhancement of the affinity between actin and synapsin, after inhibition of 
kinase function. 
LRRK2 interacts with SV2A, a neuronal protein involved in Ca
2 +
 -dependent exocytosis 
(Chang and Sudhof, 2009). SV2A interacts with synaptotagmin, a Ca
2+
 sensor protein in 
the membrane of the pre-synaptic axon terminal that interacts with the SNARE complex 
(Soluble NSF Attachment Protein Receptor) under Ca
2+
-free conditions and translocates to 
the lipid membrane when is bound to Ca
2+
 . The interaction of SV2A with Synaptotagmin 
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is negatively modulated by Ca
2 + 
and positively modulated by SV2A phosphorylation. 
LRRK2 likely phosphorylates SV2A, thus increasing the bound fraction of Synaptotagmin 
and promoting vesicle fusion with the presynaptic membrane. In addition, LRRK2 
interacts with NSF, a protein involved in the dissociation of the SNARE complex (Tong et 
al., 2009). LRRK2 was shown to interact via phosphorylation of the 
AP2/clathrin/dynamin-1 complex (Piccoli et al., 2011), and all these proteins participate in 
the first event of endocytosis of synaptic vesicles. Another possible target of LRRK2 may 
be the clathrin chains and the AP2 complex: the kinase domain likely modulates the 
binding to the membrane (Fingerhut et al., 2001). LRRK2 might therefore regulate the 
endocytosis acting on the phosphorylation status of these interactors. A recent study on the 
structure of the presynaptic site reveals that LRRK2 silencing leads to a spatial 
redistribution of vesicles in terms of distance from the presynaptic membrane, alters 
recycling dynamics and increases vesicle kinetics, thereby proving that LRRK2 plays a 
role in this mechanism (Piccoli et al., 2011). Finally, LRRK2 phosphorylates endofilline A 
(EndoA), a conserved protein that is critically involved in synaptic vesicle endocytosis. In 
vitro experiments demonstrated that LRRK2-mediated EndoA phosphorylation affects 
membrane tubulation and association. This phosphorylation modulates the endocytosis of 
synaptic membrane in vivo, blocking the separation of synaptic proteins from the 
membrane (Matta et al., 2012). These features suggest that LRRK2 facilitates efficient 
vesicle formation in synapses, through its kinase activity.  
Of note, because LRRK2 levels are particularly low in nigral dopaminergic neurons as 
compared with their high expression in striatal medium-sized spiny projection neurons 
(MSNs) (Mandemakers et al., 2012), the possibility that LRRK2 plays an important role on 
the postsynaptic side has been hypothesized. Interestingly, recent studies show that 
LRRK2 interacts with PKA, which mediates important signaling pathways critical for 
neuron function, in MSNs. At the postsynaptic side, PKA signaling is activated by DA 
acting via D1 DA receptors. In addition, PKA regulates glutamatergic transmission by 
modulating channel properties through direct phosphorylation, and its activity is modulated 
by A kinase anchoring proteins (AKAPs), which recruit PKA to distinct locations placing 
kinase close to their appropriate substrates. LRRK2 is considered to be an AKAP-like 
regulator of the subcellular distribution of a PKA subunit, PKARIIβ, which is particularly 
abundant in MSNs. In particular LRRK2 seem to acts as a negative modulator of PKA in 
the MSNs during synaptogenesis and in response to DA receptor activation (Parisiadou et 
al., 2014).  
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LRRK2: animal models  
 
In the last decade, under the impulse of the discovery of LRRK2 and its role in PD, cellular 
and animal models have been developed that provided important insights into the 
pathobiology of LRRK2, representing a fundamental tool to identify and validate the 
molecular and cellular mechanisms underlying a genetically-linked disease. Traditionally, 
animal models of PD have been generated using substances able to mimic the dysfunction 
of nigrostriatal transmission by blocking DA release and DA receptors (reserpine and 
neuroleptics; functional models) or by destroying DA neurons (neurotoxins  6-OHDA; 
(Ungerstedt et al., 1974) or MPTP (Langston and Ballard, 1983) ; neurodegeneration 
models) (Dauer and Przedborski, 2003). These pharmacological models have had 
enormous value in helping understand the consequences of nigrostriatal dopaminergic cell 
loss, in developing neuroprotective approaches and testing symptomatic/neuroprotective 
therapies. Unfortunately, these models replicate only partly  the neuropathological features 
of human PD and have limited predictivity value. Moreover, the growing demand of 
understanding the pathophysiological mechanisms of familial PD would remain unfulfilled 
using these models.  
Numerous new models of PD based on genetic manipulation have been generated over the 
last ten years (Daniel and Moore, 2014; Melrose et al., 2006). Intense efforts have focused 
on the generation of LRRK2 animal models, although these have proved somewhat limited 
in terms of recapitulating the whole phenotype of human PD (Beal, 2010). Nonetheless, all 
current LRRK2 models present unique differences and offer different advantages. Some 
LRRK2 models display different LRRK2-related phenotypes in terms of motor deficits, 
cytopathology, changes in dopaminergic neurotransmission, whereas other models, such as 
worms,flies certain transgenic rodent models, and rodent viral models show sustained 
dopaminergic neurodegeneration upon overexpression of human G2019S LRRK2 mutation 
(Daniel and Moore, 2014). To note, rodent models represent the most important tool to 
understand the pathological function of LRRK2 because genomic analysis reveal that 
Drosophila and C. elegans do not contain true orthologs of human LRRK2, and the 
absence of basal ganglia circuitry in invertebrates together with their short life span make 
them imperfect models for studying PD. For these reasons, different rodent models have 
been developed. 
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LRRK2 knockout models 
To study the role of LRRK2 in the brain, different groups analyzed the impact of genetic 
deletion of LRRK2. Different approaches have been used to generate LRRK2 knockout 
(KO) models, including deletion of different exons or promoters, and as a consequence, 
different results have been obtained. LRRK2 KO mice obtained through deletion of the 
kinase domain (exon 40) or the GTPase domain (exon 2; exon 1 and exon 29-30) encoding 
regions, display an intact nigrostriatal dopaminergic pathway up to 2 years of age. 
Moreover, mice are viable, fertile, do not display motor deficits and do not exhibit altered 
sensitivity to MPTP-induced neurotoxicity. In addition, neuropathological features 
including -synuclein accumulation or aggregation in the brain, ubiquitin accumulation, 
gliosis or altered neuronal structure, are absent in LRRK2 KO mice (Andres-Mateos et al., 
2009; Tong et al., 2010). Conversely, a recent study (Hinkle et al., 2012) shows that the 
deletion of exon 41, that encodes the activation hinge of the kinase domain, induces 
abnormal exploratory activity in 20-month-old LRRK2 KO mice, without affecting the 
nigrostriatal dopaminergic pathway. Of note, different independent groups showed a 
relationship between LRRK2 removal and age-dependent kidney and lung abnormalities, 
including reduced size due to increased apoptosis, enhanced autophagic activity, altered 
morphology with prominent -synuclein and ubiquitin accumulation (Herzig et al., 2011; 
Tong et al., 2012). Furthermore, although proliferation and survival of neural precursors is 
not altered in LRRK2 KO mice, and the loss of LRRK2 has no effect on the spine 
dynamics in MSNs (Hinkle et al., 2012), the immature neuroblasts show enhanced 
dendritic branching and complexity while the density of mossy fibers projecting from the 
dentate gyrus to the hippocampal CA3 region is increased (Paus et al., 2013). This suggests 
a regulatory role for LRRK2 in adult neurogenesis. 
 
LRRK2 transgenic models 
The generation of inducible transgenic mice overexpressing human LRRK2 under 
transcriptional control of a tetracycline operator (TetO)-regulated promoter, crossed with 
transgenic mice expressing a Tet transactivator (tTA) from the CamKIIa promoter 
(Parisiadou et al., 2009), provide interesting evidence for the pathological interaction of 
LRRK2 and -synuclein in PD. Despite no signs of neurodegeneration, but only altered 
microtubule organization and Golgi fragmentation, were detected in these transgenic lines, 
the overexpression of WT or G2019S LRRK2 accelerated the progression of A53T -
synuclein-mediated neuropathology (Lin et al., 2009). Unfortunately, to date no consistent 
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evidence can explain whether LRRK2 increases -synuclein neuronal damage and why the 
pathological interaction of these two proteins is restricted to specific neuronal populations. 
Recently, a new transgenic line has been generated, in which the expression of G2019S 
and R1441C LRRK2 has been obtained under the transcriptional control of a hybrid CMV-
enhanced human platelet derived growth factor -chain promoter (CMVe- PDGFb) 
(Ramonet et al., 2011). Interestingly, although no alteration in locomotive activity or in 
DA striatal levels and re-uptake were detected, the overexpression of G2019S LRRK2 
induced a progressive degeneration of nigrostriatal dopaminergic neurons in mice. 
Conversely, R1441C LRRK2 transgenic mice exhibited an impairment in locomotor 
activity and a reduction in catecholamine levels in the cerebral cortex. In addition, the 
overexpression of G2019S or R1441C LRRK2 induced the accumulation of autophagic 
vacuoles and damaged mitochondria in the brains of aged mice, and increased tau 
phosphorylation without changing ubiquitin or -synuclein levels (Ramonet et al., 2011). 
Interestingly, the expression of I2020T LRRK2 under the control of another promoter 
(CMV),displayed a transient impairment of locomotor activity, reduced striatal dopamine 
levels, fragmented Golgi apparatus, and an elevated degree of tubulin polymerization 
associated with reduced neurite length (Maekawa et al., 2012). Zhou and coworkers 
generated constitutive and inducible lines of transgenic rats expressing G2019S LRRK2 
(Zhou et al., 2011). They showed that constitutive expression of LRRK2 fails to induce 
locomotor abnormalities, whereas the conditional expression of LRRK2 in adults causes 
impaired DA re-uptake leading to enhanced locomotor activity. This suggests an 
involvement of the DA transporter (DAT). Unfortunately, this behavioral alteration is not 
associated with pathological dopaminergic features such as -synuclein or ubiquitin 
inclusion. This model likely recapitulates early dopaminergic neuronal dysfunction 
potentially akin to asymptomatic subjects carrying the G2019S mutation (Zhou et al., 
2011). 
In addition to the above mentioned transgenic animals, different groups generated models 
using the bacterial artificial chromosome (BAC) construct which typically randomly 
integrates within the genome at a lower copy number than mini-gene cassettes used for the 
conventional transgenic models. Using a BAC clone expressing the entire mouse LRRK2 
genomic sequence, Li and colleagues showed that expression of WT or G2019S LRRK2 
alters striatal dopamine transmission in an opposite manner. Indeed WT BAC LRRK2 
mice have enhanced striatal dopamine release and are hyperactive, while G2019S BAC 
LRRK2 mice show normal motor function, but display an age-dependent decrease of 
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striatal DA release (Li et al., 2010). Unexpectedly, WT LRRK2 BAC mice exhibit, albeit 
to a lesser extent than G2019S BAC mice, a number of phospho-tau-positive cells in 
striatum. G2019S LRRK2 BAC mice generated by Melrose and coworkers (Melrose et al., 
2010) showed reduced extracellular DA levels in striatum and an age-dependent increase 
in tau levels and phosphorylation, suggesting altered tau metabolism. Furthermore G2019S 
LRRK2 BAC mice also exhibited reduced adult neurogenesis (Winner et al., 2011) and 
altered neurite outgrowth and spine density of hippocampal neurons. Collectively, studies 
in BAC mice show a neuropathological phenotype characterized by dysfunction of 
nigrostriatal dopaminergic neurotransmission, and suggest a probable role for LRRK2 in 
the regulation of motor function, although they do not exhibit the dopaminergic 
neurodegeneration shown by the transgenic models (Ramonet et al., 2011). Simultaneously 
with the generation of transgenic models, different groups adopted other approaches, such 
as developing knockin (KI) mice or directly delivering genes into the rodent brain by the 
use of viral vectors. LRRK2 R1441C KI mice have been generated by introducing the 
R1441C mutation into exon 31, thereby allowing its expression under the control of 
endogenous regulatory elements. Unfortunately, this model failed to summarize the 
principal features of the PD phenotype, showing only an impairment in amphetamine-
stimulated locomotor activity, altered dopamine D2 receptor-mediated function in the 
striatum and reduced catecholamine release in cultured chromaffin cells (Tong et al., 
2009). On the other hand, acute injection of LRRK2 via viral vectors provided evidence of 
direct neuronal toxicity. Recently, two rodent models of viral-mediated LRRK2 expression 
have been reported. In the first study, Lee and coworkers, via a single unilateral striatal 
injection of herpes simplex virus (HSV) expressing a CMV-driven GFP reporter and 
untagged human LRRK2, reported a modest toxic effect of WT LRRK2 (∼10–20%) and a 
significant 50% nigral DA cell loss associated with reduced striatal DA levels following 
G2019S LRRK2 expression. In the other study, human WT or G2019S LRRK2 has been 
tagged by using a second-generation human serotype 5adenoviral (rAd) vectors. After 
striatal injection, G2019S LRRK2 expression in rats induced the progressive loss of ∼20% 
of dopaminergic neurons in the ipsilateral SN, without a corresponding reduction of striatal 
dopaminergic fiber density (Dusonchet et al., 2011).  
Unfortunately, these models display important limitations such as  the poor retrograde 
transport of adenovirus to the SN and a progressive reduction of transgene expression over 
time, making them unsuitable for long-term studies on the pathological effects of G2019S 
LRRK2 expression in vivo. 
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The main goal of this thesis work was to evaluate the role played by the kinase function of 
LRRK2 in the expression of motor phenotype and dopamine transmission in mice.  
To directly explore the impact of the kinase-enhancing G2019S mutation on motor activity 
in vivo, a longitudinal phenotyping approach was developed. To this purpose we enrolled 
two cohorts of G2019S knock-in (KI) mice and wild-type littermates (WT), and analyzed 
their motor activity from the age of 3 to 19 months, using a set of complementary 
behavioral tests, specific for akinesia, bradykinesia and overall gait ability. To confirm that 
enhanced kinase activity accounts for this phenotype we used both a genetic and a 
pharmacological approach. We first performed a parallel longitudinal study in mice 
carrying a LRRK2 mutation (D1994S) that impairs kinase activity (kinase-dead, D1994S 
KD), in comparison with their own WT. Then we tested the ability of small molecular-
weight ATP analogous LRRK2 kinase inhibitors to reverse the hyperkinetic phenotype of 
G2019S KI mice. 
In order to investigate whether the hyperkinetic phenotype of G2019S mice was associated 
with dysfunction of striatal dopamine neurotransmission, in the second part of this study 
we carried out a series of behavioral, biochemical, and neurochemical experiments. The 
motor responses of these mice to DA receptor agonists and antagonists were analyzed. 
Moreover we focused our attention on the impact of G2019S LRRK2 mutation on DA 
reuptake and release processes, using in vitro and in vivo (microdialysis) techniques.  
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METHODS 
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SUBJECTS 
Male homozygous LRRK2 G2019S KI and D1994S KD mice backcrossed on a C57Bl/6J 
background were used in this study. Mice were obtained from Novartis Institutes for 
BioMedical Research, Novartis Pharma AG (Basel, Switzerland) at the age of about 2 
months, and accommodated in the vivarium of the University of Ferrara. Male non-
transgenic wild-type (WT) mice were littermates obtained from the respective 
heterozygous breeding. The mice used in our study were generated at Novartis 
laboratories, and were previously characterized from several biochemical and 
neuropathological standpoints, although motor analysis was limited to the open field in 5-
month old animals (Herzig et al., 2011). Mice employed in the study were kept under 
regular lighting conditions (12 h light/dark cycle) and given food and water ad libitum. 
Experimental procedures involving the use of animals were approved by the Ethical 
Committee of the University of Ferrara and the Italian Ministry of Health (licenses 
171/2010-B and 318/2013-B). Adequate measures were taken to minimize animal pain and 
discomfort. 
 
BEHAVIORAL ANALYSIS 
Experimental design: longitudinal study (Part 1) 
The longitudinal study was conducted on two cohorts of G2019S KI (n = 19) and their WT 
(n = 12) littermates. Mice were subjected to motor tests at 3, 6, 10, 15 and 19 months (Fig. 
4). D1994S KD and their WT mice (n= 10 each) were tested at 3, 6, 10 and 15 months 
(Fig. 4). Separate, age-matched cohorts of 3, 10, 14 and 18-month-old WT and G2019S KI 
mice (6–8 mice per group) were enrolled in transversal behavioral studies, to parallel the 
results of the longitudinal study. Finally, other cohorts of mice (n= 10 each genotype) were 
used for pharmacological studies with LRRK2 kinase inhibitors at 6, 12 and 15 months 
(G2019S KI), or 12 months (D1994S KD). 
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Fig. 4. Experimental design adopted in longitudinal study. 
 
LRRK2 kinase inhibitor administration 
Twelve-month-old mice were administrated i.p. with the LRRK2 kinase inhibitor H-1152 
(Nichols et al., 2009; Sasaki et al., 2002; Tamura et al., 2005) at two different dose levels 
(0.1 and 1 mg/kg), or with the LRRK2 kinase inhibitor Nov-LRRK2-11 (Herzig et al., 
2011; Troxler et al., 2013), at two different dose levels (1 and 10 mg/kg) for the indicated 
time. H-1152 was dissolved in 0.9% saline solution whereas Nov-LRRK2-11 in 3% 
DMSO/3% Tween 80. 
 
Experimental design: study on dopaminergic transmission (Part 2) 
Pharmacological studies were performed on two cohorts of 11-16 month-old G2019S KI 
(n= 8-10) and their WT (n= 7-9) littermates. Prior to pharmacological testing, animals were 
trained for approximately 6 days to the specific motor tasks until their performance became 
reproducible. Tests were repeated in a fixed sequence before (control session) and at 
different time-points (depending on the experiment) after drug administration. 
Experimenters were unaware of genotype and treatments. Separate cohorts of 19 months 
old G2019S KI and WT mice were enrolled in neurochemical analysis by using in vivo 
microdialysis (18-16 mice per group). 
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Drugs administration 
Eleven-month-old mice were acutely administrated i.p. with the D2/D3 receptor antagonist 
haloperidol at the dose of 0.3 mg/kg, or with the D2/D3 receptor agonist pramipexole at 
four different dose levels (0.0001-0.001-0.01 and 0.1 mg/kg (Viaro et al., 2013). Sixteen-
month-old mice were injected i.p. with D1/D5 receptor antagonist SCH-23390 at the dose 
of 0.01 mg/kg, or with the DAT inhibitor GBR-12783 at two different dose levels (6 and 
20 mg/kg). Seventeen-month-old G2019S KI mice were administrated i.p. with the LRRK2 
kinase inhibitor Nov-LRRK2-11 (Herzig et al., 2011; Troxler et al., 2013) at the dose of 10 
mg/kg, and 15 min, later with GBR-12783 (20 mg/kg; i.p.). Haloperidol, pramipexole and 
SCH-23390 were dissolved in 0.9% saline solution; GBR-12783 was dissolved in 0.3 % 
DMSO /0.9% saline solution whereas Nov-LRRK2-11 in 3% DMSO/3% Tween 80/0.9%  
saline solution. 
 
Bar test 
Originally developed to quantify morphine-induced catalepsy (Kuschinsky and 
Hornykiewicz, 1972), this test measures the ability of the animal to respond to an 
externally imposed static posture. Also known as the catalepsy test (for a review see 
(Sanberg et al., 1988)), it can also be used to quantify akinesia (i.e. time to initiate a 
movement) also under conditions that are not characterized by increased muscle tone (i.e. 
rigidity) as in the cataleptic/catatonic state. Mice were gently placed on a table and 
forepaws were placed alternatively on blocks of increasing heights (1.5, 3 and 6 cm). The 
time (in seconds) that each paw spent on the block (i.e. the immobility time) was recorded 
(cut-off time of 20 s). Performance was expressed as total time spent on the different 
blocks. 
 
Drag test 
Modification of the ‘wheelbarrow test’ (Schallert et al., 1979), this test measures the ability 
of the animal to balance its body posture with the forelimbs in response to an externally 
imposed dynamic stimulus (backward dragging) (Marti et al., 2005). It gives information 
regarding the time to initiate and execute (bradykinesia) a movement. Animals were gently 
lifted from the tail leaving the forepaws on the table, and then dragged backwards at a 
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constant speed (about 20 cm/s) for a fixed distance (100 cm). The number of steps made by 
each paw was recorded. Five to seven determinations were collected for each animal. 
 
Rotarod test 
The fixed-speed rotarod test (Rozas et al., 1997) measures different motor parameters such 
as motor coordination, gait ability, balance, muscle tone and motivation to run. Mice were 
tested over a wide range of increasing speeds (0–55 rpm; 5 rpm steps, increased every 180 
s) on a rotating rod (diameter of the cylinder 8 cm) (Marti et al., 2004; Viaro et al., 2008) 
and the total time spent on the rod was recorded. 
 
Spontaneous motor activity 
The open field test was used to measure spontaneous locomotor activity in 15-month-old 
mice. The ANY-maze video tracking system was used (Ugo Basile, application version 
4.52c Beta) as previously described (Rizzi et al., 2008). Briefly, mice were placed in a 
square plastic cage (40 × 40 cm), one mouse per cage, and ambulatory behavior (horizontal 
activity) was monitored for 60 min with a camera. Four mice were monitored 
simultaneously each experiment. Total distance traveled (m) and immobility time (sec) 
were recorded. 
 
In vivo microdialysis 
Two concentric microdialysis probes (1 mm Cuprophane membrane with a 6 kDa cut-off; 
AgnTho’s, Stockolm, Sweden) were stereotaxically implanted in both dorsal striata 
(coordinates from the bregma: AP +0.6, ML ±2.0, DV −2.0; Paxinos and Franklin, 2001; 
Fig. 5) of  isoflurane-anesthetized mice. Twenty-four hours after implantation, probes were 
perfused (2.1 µl/min) with a modified Ringer solution (in nM CaCl2 1.2; KCl 2.7; NaCl 
148 and MgCl2 0.85) and samples were collected every 20 min (Bido et al., 2011; Mabrouk 
et al., 2010; Volta et al., 2010) after a 6 h wash-out period. Experiments were run at 24, 
and 48 h after implantation, and treatments were randomized. GBR-12783 and Nov-
LRRK2-11 were administrated i.p. at the respective dose of 20 mg/kg  and 10 mg/kg. At 
least three baseline samples were collected before drug treatment. At the end of the 
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experiments, animals were sacrificed and the correct placement of the probes was verified 
histologically.  
 
Fig. 5. Probe position during in vivo microdialysis experiments (Paxinos and Franklin, 2001). 
 
Neurochemical analysis using LC-MS 
Dopamine (DA), glutamate and GABA concentrations in dialysates were analyzed using a 
benzyolation derivatization LC-MS method described by (Song et al., 2012). Briefly, 5 µl 
dialysate samples were derivatized by adding 2.5 µl of 100 mM sodium tetraborate, 2.5µl 
of 2% benzoyl chloride in acetonitrile, and then 2.5 µl of a stable 13C benzoylated isotope 
internal standard mixture was then added to improve quantitation. A Thermo Fisher Accela 
UHPLC (Waltham, MA) system automatically injected 5 µl of the sample onto a Waters 
(Milford, MA) HSS T3 reverse phase HPLC column (1 mm X 100 mm, 1.8 µm). Mobile 
phase A consisted of 10 mM ammonium formate and 0.15% formic acid. Mobile phase B 
was pure acetonitrile. Analytes were detected by an Thermo Fisher TSQ Quantum Ultra 
triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) 
mode. Run times were approximately 6 min. 
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EX VIVO STUDIES  
Synaptosomes preparation 
Mice were anesthetized and decapitated, the brains were quickly removed, and striatal 
tissue was rapidly dissected. To prepare synaptosomes, striatal tissue from each mouse was 
homogenized in ice-cold 0.32 M sucrose (pH 7.4) with a Teflon-glass homogenizer and 
centrifuged at 1000 g for 10 min at 4°C. The supernatant was then centrifuged at 12,000 g 
for 20 min at  4°C. The resultant pellet was resuspended in binding buffer (50 mM Tris 
HCl, pH 7.4, 100 mM NaCl) for [3H]-WIN 35,428 saturation binding experiments or ice-
cold uptake buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM 
KH2PO4, 10 mM D-glucose, 25 mM HEPES, 0.1 mM pargyline, and 0.5 mM L-ascorbic 
acid, pH 7.4) for DA uptake assays. 
 
[
3
H]-WIN 35,428 saturation binding experiments 
Saturation binding experiments were carried out with [
3
H]-WIN 35,428 (specific activity 
84 Ci/mmol; Perkin-Elmer, Boston, MA, USA) as radioligand (Chen et al., 1996). 
Synaptosomes from WT (n = 3) and G2019S KI (n = 3) mice were incubated in assay 
buffer (50 mM Tris HCl, pH 7.4, 100 mM NaCl) with different concentrations (0.5 – 50 
nM) of radioligand for 120 min at 4°C. Nonspecific binding was determined in the 
presence of 5 µM GBR-12783. At the end of the incubation time, bound and free 
radioactivity were separated by filtering the assay mixture through Whatman GF/B glass 
fiber filters in a Brandel cell harvester (Brandel Instruments, Unterföhring, Germany). 
Filter bound radioactivity was counted in a Perkin Elmer 2810TR scintillation counter 
(Perkin-Elmer, Boston, MA, USA). 
 
Dopamine Uptake Assay 
Synaptosomal preparations from G2019S KI (n = 3) and WT (n = 3)  mice were incubated 
for 5 min at 37°C with 20 nM [3H]-DA (specific activity 40 Ci/mmol; Perkin-Elmer, 
Boston, MA, USA) isotopically diluted with varying concentrations of unlabeled DA to 
obtain final DA  concentrations in the range 20 nM – 2.0 µM. Non-specific dopamine 
uptake was evaluated in the presence of 5 µM GBR-12783. The reaction was terminated by 
filtering the assay mixture through Whatman GF/B glass fiber filters using a Brandel cell 
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harvester (Brandel Instruments, Unterföhring, Germany). The filter-bound radioactivity 
was counted using a Perkin Elmer Tri Carb 2810 TR scintillation counter. Specific DA 
uptake, defined as the difference between DA accumulated in the absence and in the 
presence of GBR-12783, was expressed as picomoles per milligram of protein per minute 
(Zhu et al., 2009).  
The protein concentration was determined according to a Bio-Rad method with bovine 
albumin as standard reference. Kinetic parameters (Vmax and Km) were determined using 
Prism 5.0 (GraphPad Software Inc., San Diego, CA). 
 
In vivo PK study 
In order to gain insights on the brain penetration of  Nov-LRRK2-11, a screening cassette 
approach was used, as previously described (Troxler et al., 2013). Adult male C57Bl/6 
mice (20–30 g, Iffa-Credo, France) were orally administered (by gavage) with Nov-
LRRK2-11 (suspended in carboxymethylcellulose 0.5 % w/v in water with Tween 80 at 
0.5% v/v) at a dose of 3 mg/kg p.o.. Volume of oral administration was 10 mL/kg body 
weight. After drug cassette administration, blood (~50 μL in EDTA) was collected at 
different time points (15 min, 30 min, 1, 2, 4, 8 and 24 h postdose, n = 3 mice per time-
point,) either by puncture of the sublingual vein (~70 μL/mouse, under light anesthesia) or 
by puncture from the vena cava at sacrifice (~300 μL/mouse). Moreover, at sacrifice (at 15 
min, 1, 4, and 24 h post-dose), brains were removed, weighted and immediately frozen on 
dry ice. Blood and brain samples were stored at −20 °C until analysis. Samples were 
analyzed for Nov-LRRK2-11 content with LC–MS/MS methodologies. 
 
Cell cultures and treatments 
NIH3T3 cells were cultured in Dulbecco's Modified Eagle's medium (Life technologies) 
supplemented with 10% fetal bovine serum (Life technologies), penicillin and 
streptomycin (Life technologies) and maintained at 37 °C in a 5% CO2 controlled 
atmosphere. H-1152 and Nov-LRRK2-11 were dissolved in 0.9% saline solution and in 3% 
DMSO/3% Tween 80/0.9% saline, respectively. Inhibitors were used at the indicated 
concentrations, and equivalent volumes of saline solution were used as control. Inhibitors 
were added to the culture medium for 90 min before cell lysis. 
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Cells and tissue lysis 
NIH3T3 cells, as well as striatum and cortex obtained from brain dissection were 
homogenized and solubilized in lysis buffer (20 mM Tris– HCl pH 7.5, 150 mM NaCl, 
1mM EDTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4) 
supplemented with 1% Triton X-100 (Sigma Aldrich) and protease inhibitor cocktail 
(Roche), then cleared at 14,000 g at 4 °C for 30 min. Protein concentrations were 
determined using the bicinchoninic acid assay (BCA) as manufacturer's instructions 
(Thermo Scientific). 
 
Western blotting 
Proteins were separated by electrophoresis into pre-casted 4-20% SDS-PAGE gels 
(Biorad) and subsequently transferred onto Immobilon-P membrane (Millipore). 
Membranes were first incubated 1 h at RT with rabbit anti-LRRK2 phospho Ser935 (1:300, 
Abcam, RabMAbs cat#ab133450), rabbit anti-LRRK2 UDD3 (1:1000, Abcam, RabMAbs 
cat# ab133518), rabbit anti-DAT (1:1000, Sigma Aldrich), anti-VMAT2 (1:300, Sigma 
Aldrich), mouse anti-GADPH (1:4000, Millipore) and mouse anti-tubulin (1:3000, 
Millipore) then with HRP-conjugated secondary antibodies (Sigma) for 1 h at room 
temperature and then incubated with enhanced chemiluminescent (ECL) western blot 
substrate (Thermo Scientific). 
 
Immunohistochemistry 
Mice were deeply anesthetized (ketamine 85 mg/kg; i.p.) and transcardially perfused with 
4% paraformaldheyde in Phosphate Buffer Solution (PBS; 0.1 M, pH 7.4). Brains were 
removed, transferred to a 20% sucrose solution in PBS for cryoprotection and then stored 
at -80°C. They were then cut with a cryostat (Leica, Nussloch, Germany) to obtain 35 µm 
coronal sections of Striatum (STr; AP from +1,42 to +0,14 from bregma) and Substantia 
Nigra Pars Compacta (SNc; AP from -3,16 to -3,52 from bregma; Paxinos and Franklin, 
2001). 
Sections were rinsed in TBS (Tris Buffered Saline),  incubated for 1 hr with blocking 
solution (Bovin Serum Albumin; 3% in TBS) and then incubated overnight with TH 
primary antibody (Purified rabbit polyclonal antibody; 1:500 in BSA 1% TBS; Merck 
46 
 
Millipore, Darmstadt, Germany) and with a fluorescent marker of Nissl Bodies 
(Neurotrace; 1:150; Life Technologies, Grand Island, NY, USA). After being rinsed in 
TBS, sections were incubated with a secondary antibody (AlexaFluor 488, Goat anti-rabbit 
IgG; 1:500 in TBS; Life Technologies). Sections were then mounted on slides with 
Shur/Mount Water Based (Hatfield, USA) 
Stereology and neuron counting  
Stereological analysis was performed with a fluorescence microscope (Leica, Nussloch, 
Germany) equipped with a motorized Z and X-Y stage; for each animal 5 slices were used 
in order to analyze the entire volume of the SNc and the area was identified with 10x 
magnification according to the  mouse brain atlas (Paxinos and Franklin, 2001); the area 
was then divided into 3 rectangles (350 x 260 µm) and each rectangle was then amplified 
with 40x magnification. To count TH-immunoreactive neurons (phenotypic marker) and 
Neurotrace stained cells (structural marker) in SNc 8 images of the same rectangle were 
taken at different levels of the Z axis. The images were then mounted and analyzed off-line 
using ImageJ (NIH, USA). Every neuron appearing on focus was counted. Average 
number of neurons ± SEM was calculated for each group.   
To analyze dopaminergic striatal innervation, striatal sections were incubated for 1 hr with 
a blocking solution (Goat Serum 5% in TBS) and overnight with the same TH antibody 
described above. After rinsing, sections were incubated for 40 min with the same 
secondary antibody described above and then mounted on slides. Images were taken at 10x 
magnification with a fluorescence microscope and later analyzed off-line for optical 
intensity with ImageJ, using Corpus Callosum (ACC) as background. 
 
Data presentation and statistical analysis 
Data are expressed as absolute values and are mean ± SEM (standard error of the mean) of 
n mice. To assess the significance of behavioral changes over the 19-month longitudinal 
study (Figs. 1-2) a linear mixed-model repeated measures analysis using the REPEATED 
statement was used, followed by the Bonferroni test (PROCMIXED, SAS, version 9.2, 
SAS Institute Inc, Cary, NC, USA). Genotype was set as discrete variable, weight as 
continuous variable. This allowed to verify whether changes in weight could account for 
changes in behavioral performances. Statistical analysis of drug effect was performed by 
one-way repeated measure (RM) analysis of variance (ANOVA) followed by the 
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Newman–Keuls test for multiple comparisons, or by two-way ANOVA followed by 
Bonferroni test for multiple comparisons (Table 2). The Student's t-test, two tailed for 
unpaired data was used to compare two groups of data. P-values < 0.05 were considered to 
be statistically significant. 
 
Drugs 
Haloperidol hydrochloride, SCH23390 hydrochloride, pramipexole dihydrochloride, GBR-
12783 dihydrochloride and quinpirole hydrochloride were purchased from Tocris 
Bioscience (Bristol, UK). H-1152 was purchased from SiChem GmbH -BITZ (Bremen, 
Germany) and Nov-LRRK2-11 was obtained from Novartis Institutes for BioMedical 
Research, Novartis Pharma AG (Basel, Switzerland). 
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Part 1 
Behavioral analysis of mice carrying mutations within the LRRK2 kinase domain  
Characterization of motor phenotype in aging G2019S KI and WT mice 
In order to investigate whether the kinase-enhancing G2019S point mutation in murine 
LRRK2 affects motor performance, two cohorts of G2019S KI mice and age-matched WT 
littermates (WT) were enrolled in a longitudinal study in which motor activity was 
measured using the fixed sequence of bar, drag and rotarod tests from 3 through 19 months 
of age. 
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Fig. 6. Motor phenotype in mice during aging. Mice were subjected to a set of tests, namely the bar (A), drag (B) and 
rotarod (C) tests, from 3 up to 19 months of age. In addition, an open field test was performed in 15-month old animals 
(D–E). Motor activity was expressed as immobility time (sec; A, D), number of steps (B), time on rod (sec; C), and total 
distance traveled (m; E). Data are means ± SEM of 9–10 (3–15 months) or 6 (19 months) mice per group, and were 
analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple comparisons. Differences 
between genotypes at the single time-point levels were evaluated using the Student t-test, two tailed for unpaired data. 
*P<0.05, **P<0.01 different from3-month-old mice of the same genotype. °P < 0.05,°°P < 0.01 different from age-
matched littermates. 
 
Immobility time of G2019S KI mice in the bar test (8.5 ± 2.1 s) was not different from that 
of WT (12.4 ± 2.9 s) at 3 months (Fig. 6A). Immobility time increased along with aging in 
WT mice reaching a maximum of 33.7 ± 2.3 s at 19 months. Conversely, G2019S KI mice 
did not become akinetic with aging, showing similar performances across the study. The 
difference between genotypes was evident starting at 6 months (~2-fold), and attained 
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stable values (~3-fold) from 10 months onward. In the drag test (Fig. 6B), a significant 
effect of genotype (F1,75 = 91.11, p < 0.0001), time (F4,75 = 26.78, p = 0.0027) and their 
interaction (F4,75 = 6.11, p = 0.0003) was found. As in the bar test, no significant influence 
of weight was observed (F1,75 = 1.54, p = 0.22). G20 19S KI mice showed a significant 
23% greater stepping activity than WT at 3 months (21.7 ± 1.1 vs 17.7 ± 0.7 steps, 
respectively). This difference became 2–3-fold larger in older animals, since stepping 
activity of WT mice progressively worsened over time, reaching 3.4 ± 0.3 steps at 19 
months, whereas that of G2019S KI mice remained stable up to 15 months, showing a 
significant decline only at 19 months (10.7 ± 1.1 steps). Different from the bar and drag 
test, no significant effect of genotype was found in the rotarod test (F1,75 = 0.01, p = 0.92), 
but a significant effect of time (F4,75 = 8.24, p < 0.0001) and genotype × time interaction 
(F4,75 = 3.81, p = 0.0071). Also in this test, the influence of weight was not significant 
(F1,75 = 0.03, p = 0.86). Mild improvement of rotarod performance in WT mice was 
observed along with aging (10 and 19 months), whereas that of G2019S KI mice remained 
stable throughout the study (Fig. 6C). The open field test was performed in 15-month-old 
animals. G2019S KI mice showed 42% shorter immobility time (t= 2.53, df=8, p= 0.036; 
Fig. 6D) and 43% longer distance traveled (t = 4.15, df = 8, p = 0.003; Fig. 6E) compared 
to WT. To confirm the hyperkinetic phenotype of G2019S KI mice, the bar, drag, rotarod 
and open field tests were repeated in age-matched separate cohorts of 3, 10, 14 and 18-
month-old-mice, not involved in the longitudinal study (Fig. 7). These experiments 
substantially confirmed that G2019S KI mice were hyperactive, with significant 
differences with WT emerging already at 3 months in the bar and drag tests, and at 10 
months in the open field. As in the longitudinal study, no differences in rotarod 
performance were observed between age matched cohorts of WT and G2019S KI mice. 
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Fig. 7. Motor performance was evaluated in age-matched cohorts of  3, 10, 14 and 18-month-old G2019S KI and WT 
mice, using the bar (A), drag (B), rotarod (C) and open field (D-E) tests. Motor activity was expressed as immobility time 
(sec; A, D), number of steps (B), time on rod (sec; C), and total distance travelled (m; E). Data are means ± SEM of 6-8 
mice per group, and were analyzed using the Student t-test two-tailed for unpaired data. °P<0.05,°°P<0.01 different from 
age-matched WT. 
 
G2019S KI mice had throughout the study a lower body weight than WT (Table 2). The 
difference was 14% on average. In the bar test (Fig. 6A), a significant effect of genotype 
(F1,75 = 45.52, p < 0.0001), time (F4,75 = 4.47, p = 0.0027) and their interaction (F4,75 = 
6.40, p = 0.0002) was found. The influence of weight was found not to be significant (F1,75 
= 3.50, p = 0.07). 
 
 Age (months)     
Genotype 3 6 9 15 19 
G2019S KI (g) 23.8 ± 0.9**(11) 27.5 ± 0.4**(11) 30.4 ± 0.4** (11) 30.9 ± 0.4** 
(11) 
31.8 ± 0.4* 
(6) 
WT (g) 28.8 ± 0.8 (9) 31.5 ± 0.8 (9) 34.7 ± 0.8 (9) 35.3 ± 1.2 (9) 36.2 ± 1.4 (6) 
D1994S KD (g) 25.6 ± 0.4 (10) nt 32.0 ± 0.6 (10) 33.1 ± 0.7 
(10) 
Nt 
WT(g) 26.0 ± 0.4 (9) nt 33.4 ± 0.7 (9) 34.6 ± 0.7 (9) Nt 
 
Table 2. G2019S KI mice weighed less than WT littermates throughout the study. No difference was observed between 
D1994S KD and respective WT littermates. Data are expressed in grams and are means ± SEM of the number of mice 
indicated in parentheses. *P < 0.05, **P < 0.01 different from WT (2-way ANOVA followed by the Bonferroni post hoc 
test). nt= not tested 
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Characterization of motor phenotype in aging D1994S KD and WT mice 
Since experiments in G2019S KI mice suggested that enhancement of kinase activity is 
associated with greater motor performance, we investigated if kinase activity silencing 
mutation might cause a differential effect. To this purpose, we used mice bearing the 
kinase-inactivating point mutation D1994S (D1994S KD) and age-matched WT 
littermates. No difference in weight was observed between D1994S KD and WT mice 
throughout the study (Table 2). Statistical analysis of bar test values revealed no significant 
effect of genotype (F1,67 = 0.1, p = 0.74), a significant effect of time (F3,67 = 31.23, p < 
0.001) but not a genotype × time interaction (F3,67 = 1.17, p = 0.31). Likewise, in the drag 
test, a significant effect of time (F3,67= 42.21, p < 0.001), but not of genotype (F1,67 = 0.48, 
p = 0.49) or genotype × time interaction (F3,67= 0.56, p= 0.64) was found. Only in the 
rotarod test, a significant effect of genotype (F1,67= 16.11, p= 0.0002) and time (F3,67= 
10.79, p < 0.0001) but not their interaction (F3,67= 0.63, p= 0.62) was found. Overall, basal 
activity in the bar (Fig. 8A), drag (Fig. 8B) and rotarod (Fig. 8C) test was similar between 
D1994S KD mice and their WT at any age analyzed. As expected, WT but as well D1994S 
KD mice showed a significant worsening of motor activity in the bar (increase of 
immobility time) and drag (reduction of stepping activity) tests at 10 and 15 months. 
Transient improvement of rotarod performance was observed in WT and D1994S KD mice 
at 10 months. Consistently, no difference in exploratory behavior was observed between 
genotypes in the open field at 15 months (immobility time t=0.21, df=7, p=0.84; distance 
traveled t=0.03, df=7, p=0.97; Figs. 8 D–E).  
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Fig. 8. Mice were subjected to a set of tests, namely the bar (A), drag (B) and rotarod (C) tests, starting at 3 months up to 
19 months of age. In addition, an open field test was performed in 15-month-old animals (D–E). Motor activity was 
expressed as immobility time (sec; A, D), number of steps (B), time on rod (sec; C), and total distance traveled (m; E). 
Data are means ± SEM of 10 mice per group, and were analyzed using one-way RM ANOVA followed by the Newman–
Keuls test for multiple comparisons. Differences between genotypes at the single time-point levels were evaluated using 
the Student t-test, two-tailed for unpaired data. **P < 0.01 different from 3-month-old mice of the same genotype.  
 
WT mice obtained from both colonies (G2019S KI and D1994S KD) showed substantially 
similar performances throughout the study (Tab. 3), with the exception of rotarod 
performance which was significantly lower at 3 and 6 months in WT littermates of G2019S 
KI mice. 
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 Age 
(months) 
3 6 9 15 19 
       
WT KI Bar (sec) 12.5 ± 2.9 17.4 ± 2.7 29.3 ± 3.2 34.2 ± 2.2 33.7 ± 2.3 
 Drag (steps) 17.7 ± 0.7 10.9 ± 0.7 10.5 ± 0.8 6.5 ± 1.1 3.4 ± 0.3 
 Rotarod (sec) 551.8 ± 
49.5* 
646.0 ± 
40.3* 
888.1 ± 37.7 691.9 ± 65.6 934.1 ± 40.2 
 Distance (m) nt Nt nt 64.6 ± 5.4 Nt 
 Immobility 
(sec) 
nt Nt nt 656.3 ± 95.1 Nt 
       
WT KD Bar (sec) 8.5 ± 1.0 16.9 ± 2.2 33.8  ± 3.4 34.3 ± 3.0 Nt 
 Drag (steps) 16.2 ± 1.7 12.7 ± 0.4 8.5 ± 0.3 7.9 ± 0.6  
 Rotarod (sec) 752.3 ± 39.1 913.9 ± 47.4 1075.1 ± 
90.1 
824.4 ± 44.2  
 Distance (m) nt Nt nt 78.8 ± 7.9 Nt 
 Immobility 
(sec) 
nt Nt nt 445.0 ± 77.8 Nt 
 
Table 3. A comparison between motor performances of wild-type mice used in the study, i.e. G2019S LRRK2 knock-in 
(KI) littermates (WT KI) and D1994S LRRK2 kinase-dead (KD) littermates (WT KD). Data are expressed as absolute 
values and are means ± SEM. *P<0.05, different from WT KD (Student t-test, two-tailed for unpaired data). nt = not 
tested 
 
Pharmacological inhibition of the LRRK2 kinase activity  
Effect of the LRRK2 kinase inhibitor H-1152 on motor phenotype  
Since results obtained with G2019S KI and D1994S KD mice suggest that the greater 
motor performance associated with the G2019S mutation is dependent on kinase activity, 
we next asked whether LRRK2 kinase inhibitors acutely administered to G2019S KI mice 
were effective at returning the hyperkinetic phenotypes to WT levels. We first used H-
1152, a ROCK (Rho kinase) inhibitor (Nichols et al., 2009; Sasaki et al., 2002; Tamura et 
al., 2005) which has been previously shown to display high potency against LRRK2 
(Gilsbach et al., 2012; Nichols et al., 2009). We initially confirmed that H-1152 was 
effective at inhibiting endogenous LRRK2 in NIH3T3 mouse fibroblasts, using 
dephosphorylation of Ser935 as readout of LRRK2 kinase activity, as previously described 
(Dzamko et al., 2010). As shown in Fig. 9, H-1152 induced Ser935 de-phosphorylation in 
a concentration-dependent manner, with apparent IC50 of 170 nM. 
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Fig. 9. Blots from lysates of NIH3T3 cells (A) exposed to vehicle or increasing concentrations of H-1152 (0.03–10 μM) 
for 90 min (B). Data are means ± SEM of 2 experiments performed in duplicate. 
 
We next assessed H-1152 in vivo. In 6-month-old mice, H-1152 was ineffective at 0.1 
mg/kg, but increased immobility time (treatment F2,21=5.37, p=0.013; time F1,21=0.72, 
p=0.41; time × treatment interaction F2,21=10.87, p<0.0001; Fig. 10A) and reduced 
stepping activity (treatment F2,21=4.69, p=0.021; time F1,21=22.58, p<0.0001; time × 
treatment interaction F2,21=5.93, p<0.009; Fig. 10B) of G2019S KI mice to the levels of 
WT mice at 1 mg/kg. The same dose of H-1152 did not affect rotarod performance 
(treatment F2,21=0.06, p=0.94; time F1,21=1.79, p=0.19; time × treatment interaction 
F2,21=0.02, p=0.98; Fig. 10C).  
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Fig. 10. H-1152 was administered at 0.1 and 1 mg/kg (i.p.) in 6 month-old mice, and motor activity assessed using the 
bar (A), drag (B) and rotarod (C) tests, before (time 0; basal values) and 30 min after drug administration. Data are means 
± SEM of 8 mice per group, and were analyzed using one-way RM ANOVA followed by the Newman-Keuls test for 
multiple comparisons. *P<0.05 ,**P<0.01 different from basal values. 
 
 
The time-course of the response to H-1152 (1 mg/kg) was next studied in 12-month-old 
mice (Fig. 11). Saline-treated WT and G2019S KI mice showed stable responses in the bar 
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(Fig. 11A) and drag (Fig. 11B) tests across the 24-h observation period. Administration of 
H-1152 induced a rapid (maximal within 30 min) and prolonged (up to 6 h) increase of 
immobility time (treatment F1,8=59.32, p<0.0001; time F5,8=14.25, p<0.0001; time × 
treatment interaction F5,40=14.17, p<0.0001; Fig. 11A) and reduction of stepping activity 
(treatment F1,8=14.64; p=0.005; time F5,8=14.12, p<0.0001; time × treatment interaction 
F5,40=13.61, p<0.0001; Fig. 11B) in G2019S KI mice, being ineffective in WT mice (bar 
test: treatment F1,8=0.39, p=0.84; time F5,40=2.77, p=0.03; time × treatment interaction 
F5,40=0.92, p=0.47; drag test: treatment F1,8=0.76, p=0.41; time F5,40=1.57, p=0.19; time × 
treatment interaction F5,40=1.94, p=0.11 Fig. 11A). No residual effect of H-1152 was 
detected 24 h after administration.  
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Fig. 11. Time-course of the motor effects of the LRRK2 kinase inhibitor H-1152 in 12-month-old G2019S KI mice and 
wild-type littermates (WT). H-1152 (1 mg/kg; i.p.) or saline were administered to 12-month-old mice, and motor activity 
assessed using the bar (A), drag (B) and rotarod (C) tests, before (time 0; basal values) and after (30, 90, 180, 360 min, 24 
h) drug administration. Data are means ± SEM of 6 mice per group, and were analyzed using one-way RM ANOVA 
followed by the Newman–Keuls test for multiple comparisons. *P<0.05, **P< 0.01 different from basal values. 
 
Rotarod performance was not significantly affected by H-1152 (G2019S KI: treatment 
F1,8=0.21, p=0.65; time F5,40=6.27, p<0.0001; time × treatment interaction F5,40=0.81, 
p=0.54; WT: treatment F1,8=2.94, p=0.12; time F5,40=10.85, p<0.0001; time × treatment 
interaction F5,40=0.65, p=0.64; Fig.11C). Indeed, performances worsened within 75 min 
after administration and remained stable afterwards in mice of both genotypes treated with 
saline or H-1152. Motor tests were repeated in 15-month-old mice with substantially 
similar results (Fig. 11C), although H-1152 (1 mg/kg) also mildly and transiently impaired 
rotarod performance in G2019S KI mice.  
To account for a certain compound specificity of LRRK2 activity inhibition we also treated 
D1994S KD mice and their wild-type controls (Figs. 12A-C). H-1152 (1 mg/kg) treatment 
did not affect motor activity in any genotypes (bar test: genotype F1,8=1.03, p=0.34; time 
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F4,32=0.34, p=0.84; time× treatment interaction F4,32=0.53, p=0.71; drag test: genotype 
F1,8=0.25, p=0.63; time F4,32=2.28, p=0.08; time × treatment interaction F4,32=0.34, p=0.85; 
rotarod test: genotype F1,8=2.64, p=0.14; time F4,32=3.98, p=0.01; time × treatment 
interaction F4,32=0.79, p=0.53), consistent with the lack of motor abnormalities in these 
animals.  
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Fig. 12. Time-course of the motor effects of H-1152 (1 mg/kg, i.p.) in 12-month-old D1994S KD mice and wild-type 
littermates (WT), assessed using the bar (A), drag (B) and rotarod (C) tests, before (time 0; basal values) and after (30, 
120, 360min, 24 h) drug administration. Data are means ± SEM of 6mice per group, and were analyzed using one-way 
RM ANOVA followed by the Newman– Keuls test for multiple comparisons. 
 
Effect of the LRRK2 kinase inhibitor H-1152 on LRRK2 phosphorylation at Ser935 
Finally, we evaluated in vivo on-target engagement of H-1152 by measuring LRRK2 
phosphorylation at Ser935 in ex-vivo samples of the striatum and cerebral cortex obtained 
from 12-month-old G2019S KI (Figs. 13A-B) and WT (Figs. 13C-D) mice.  
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Fig. 13. The LRRK2 kinase inhibitor H-1152 attenuated endogenous LRRK2 phosphorylation at Ser935 in striatum but 
not cerebral cortex of G2019S knock-in (G2019S KI) mice, being ineffective in wild-type littermates (WT). Three 12-
month-old LRRK2 G2019S KI mice (A–B) were used as untreated controls, and three G2019S KI mice were 
administered with H-1152 (1 mg/kg, i.p.). In parallel, five WT KI mice (C–D) were used as controls, and four WT KI 
mice were treated with the same dose of H-1152 (1 mg/kg, i.p.). LRRK2 phosphorylation was measured ex-vivo in the 
striatum (A, C) and cerebral cortex (B, D), before (time 0; T0) and 20 min after H-1152 administration. Results are mean 
± SEM of 3–5 mice per group, and were analyzed using the Student t-test, two tailed for unpaired data. To minimize 
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experimental variability, each sample was loaded in duplicate and the numbers plotted represent the mean of the two 
technical replicates. *P<0.05 different from basal values (T0). 
 
A decrease of LRRK2 phosphorylation was observed in striatum (p=0.015, t=4.05, df=4), 
but not cerebral cortex (p=0.095, t=0.98, df=4), at 20 min after administration of 1 mg/kg 
H-1152 but not later time-points (i.e. 90 and 360 min; Figs. 14A-B). Contrary to G2019S 
KI mice, no effect of H-1152 on LRRK2 phosphorylation was detected in striatum 
(p=0.30, t=1.11, df=7) or cerebral cortex (p=0.31, t=1.08, df=7) at 20 min after 
administration in WT mice (Fig. 13B-D) 
 
 
Fig. 14. The LRRK2 kinase inhibitor H-1152 did not affect phosphorylation of LRRK2 at Ser935 ex-vivo at 90 and 360 
min after administration. Twelve-month-old LRRK2 G2019S knock-in (G2019S KI) mice were treated with H-1152 (1 
mg/Kg, i.p.), and sacrificed 90 or 360 min later. LRRK2 phosphorylation was measured ex-vivo in the striatum (A) and 
cerebral cortex (B), before (time 0; T0), 90 min or 360 min after H-1152 administration. Results are the mean ± SEM of  
3 mice per group, and were analysed using one-way ANOVA followed by the Newman Keuls test. 
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Effect of the LRRK2 kinase inhibitor Nov-LRRK2-11 on motor phenotype in LRRK2 
G2019S KI and WT mice 
To confirm that the results obtained with H-1152 are due to LRRK2 inhibition and not 
other off-target kinases, we employed a second small molecule ATP analog inhibitor, Nov-
LRRK2-11,which has been recently shown to be brain penetrant and reasonably selective 
(Troxler et al., 2013). We first tested Nov-LRRK2-11 in vitro for its ability to inhibit 
LRRK2 Ser935 phosphorylation. Nov-LRRK2-11 resulted in being very potent at reducing 
LRRK2 phosphorylation in NIH3T3 cells, with IC50 of 0.38 nM (Fig. 15).  
 
Fig. 15. The LRRK2 kinase inhibitor Nov-LRRK2-11 attenuated endogenous LRRK2 phosphorylation at Ser935 in cells. 
Blots from lysates of NIH3T3 cells (A) exposed to vehicle or increasing concentrations of Nov-LRRK2-11 (0.03–10 nM) 
for 90 min (B). Data are means ± SEM of 2 experiments performed in duplicate. 
 
Next, we assessed the compound in vivo (Fig. 16). Nov-LRRK2-11 (1 and 10 mg/kg, i.p.) 
did not induce any obvious behavioral change on immobility time and step number in WT 
mice (bar test: treatment F2,13=39.83, p<0.001; time F4,52=2.33, p=0.07; time × treatment 
interaction F8,52=0.75, p=0.65; drag test: treatment F2,13=1.05, p=0.37; time F4,52=2.34, 
p=0.07; time × treatment interaction F8,52=0.95, p=0.48; Fig. 16A-B). However, Nov-
LRRK2-11 acute treatment phenocopied the motor inhibiting effects of H-1152 in G2019S 
KI mice (bar test: treatment F2,13=60.05, p<0.0001; time F4,60=29.15, p<0.0001; time × 
treatment interaction F8,60=29.15, p<0.0001; drag test: treatment F2,15=12.65, p=0.001; time 
F4,60=18.51, p<0.0001; time × treatment interaction  F8,60= 15.55, p<0.0001; Figs. 16A-B). 
Nov-LRRK2-11 was ineffective at 1 mg/kg, and induced a rapid (significant at 20 min, 
maximal at 75 min) increase in immobility time (Fig. 16A) and reduction of stepping 
activity (Fig. 16B) at 10 mg/kg. These effects were shorter lasting than those of H-1152, 
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since stepping activity was normalized and immobility time only mildly elevated at 360 
min after administration.  
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Fig. 16. The LRRK2 kinase inhibitor Nov-LRRK2-11 reversed motor phenotype in G2019S knock-in (G2019S KI) mice 
being ineffective in wild-type littermates (WT). Time-course of the motor effects of Nov-LRRK2-11 (1 and 10 mg/kg, 
i.p.), in 12-month-old G2019S KI and WT mice. Motor activity was assessed using the bar (A), drag (B) and rotarod (C) 
tests, before (time 0; basal values) and after (15, 75, 165, 360 min, 24h) drug administration. Data are means ± SEM of 
6–8 mice per group, and were analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple 
comparisons. *P<0.05, **P<0.01 different from basal values. 
 
Nov-LRRK2-11 caused a delayed reduction of rotarod performance in WT mice at 1 and 
10 mg/kg, the latter dose inducing a more rapid effect (rotarod test: treatment F2,13=0.78, 
p=0.47; time F4,52=12.96, p<0.0001; time × treatment interaction F8,52=3.52, p=0.002; 175 
min; Fig. 16C). In G2019S KI mice, the lower dose induced a response that was 
superimposable to that observed in WT, albeit more rapid in onset (within 15 min) (rotarod 
test: treatment F2,20=0.94, p=0.40; time F4,80=18.37, p<0.0001; time × treatment interaction 
F8,80=3.29, p=0.003). Behavioral data were in line with pharmacokinetic data. In fact, 
following an oral dose of 3 mg/kg Nov-LRRK2-11, brain and blood concentrations were 
maximal at 1 h, and only minimally detected at 4 h; at 24 h, compound levels were below 
detection (Fig. 17).  
 
62 
 
 
Fig. 17. Pharmacokinetic study showing blood and brain concentrations of Nov-LRRK2-11 after oral administration (by 
gavage) of the 3 mg/Kg dose. Each time-point represents the mean of 3 ± SEM of 3 mice. 
 
 
Effect of the LRRK2 kinase inhibitor Nov-LRRK2-11 on LRRK2 phosphorylation at Ser935 
To confirm in vivo LRRK2 targeting, we measured LRRK2 phosphorylation at Ser935 30 
min after Nov-LRRK2-11 (10 mg/kg) administration in 12-month old G2019S KI and WT 
animals (Fig. 18). Nov-LRRK2- 11 markedly reduced LRRK2 phosphorylation in the 
striatum and cerebral cortex of G2019S KI mice (by 75% and 50%, respectively, n=3 
animals each; striatum p=0.008, t=4.78, df=4; cortex p=0.011, t=4.41, df=4; Figs. 18A-B) 
as well as WT mice (by 60% and 80%, respectively, n=5 animals each, striatum  p=0.004, 
t=3.95, df=8; cortex p=0.044, t=2.37, df=8; Figs. 18C-D). Interestingly, in the cerebral 
cortex but not striatum, pharmacological blockade of LRRK2 kinase activity reduced 
protein LRRK2 levels (Figs. 18B and D). 
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Fig. 18. The LRRK2 kinase inhibitor Nov-LRRK2-11 attenuated endogenous LRRK2 phosphorylation at Ser935 in the 
striatum and cortex of both G2019S knock-in (G2019S KI) mice and wild-type littermates (WT). Three 12-month-old 
G2019S KI mice (A–B) were used as untreated controls, and three G2019S KI mice were administered with Nov-
LRRK2-11 (10 mg/kg, i.p.). In parallel, five WT KI mice (C–D) were used as controls, and five WT KI mice were treated 
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with the same dose of Nov-LRRK2-11 (10 mg/kg, i.p.). LRRK2 phosphorylation was measured ex vivo in the 
striatum(A, C) and cerebral cortex (B, D), before (time 0; T0) and 30min afterNov-LRRK2-11 administration. Results are 
mean ± SEM of 3–5mice per group, and were analyzed using the Student t-test, two tailed for unpaired data. *P<0.05, 
**P<0.01 different from basal values (T0). 
 
Finally, pSer935 LRRK2 and endogenous LRRK2 protein levels were monitored in 12-
month-old G2019S KI and KD mice in comparison with their WT controls (Fig. 19). 
pSer935 LRRK2 levels in striatum and cortex, as well as LRRK2 protein levels in striatum 
were similar across genotypes. Likewise, similar levels of LRRK2 were found in the cortex 
of G2019S KI and WT mice. D19994S KD levels were also in the same range of G2019S 
KI mice, although lower than those found in their littermates. 
 
Fig. 19. LRRK2 expression in the cortex (A) and striatum (B) of 12-month-old G2019S KI mice, D1994S 
KD mice, and respective WT littermates. Data are means ± SEM of 3 mice per genotype, and were analyzed 
using the Student t-test two-tailed for unpaired data. *P<0.05 different from WT 
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Part 2 
The identification of a LRRK2 kinase activity-dependent hyperkinetic phenotype resistant 
to age-related motor decline in G2019S KI mice, prompted us to investigate the underlying 
biochemical and neurochemical mechanisms. In particular, we investigated whether such a 
hyperkinetic phenotype was associated with dysregulation of dopaminergic transmission.  
 
Pharmacological manipulation of dopaminergic transmission in G2019S KI mice 
In the first series of behavioral pharmacology experiments, the responsiveness to 
dopaminergic drugs was evaluated. The fixed sequence of bar, drag and rotarod tests was 
performed in 11-month-old mice before (control session) and after systemic administration 
of the D2/D3 receptor selective antagonist haloperidol, the D1/D5 receptor selective 
antagonist SCH23390, and the D2/D3 selective agonist pramipexole. 
 
Haloperidol 
Haloperidol was injected systemically (i.p.) at the dose of 0.3 mg/kg, which was previously 
found effective in causing motor impairment in naïve mice (Mabrouk et al., 2010; Marti et 
al., 2005; Viaro et al., 2013). In the bar test (Fig. 20A), haloperidol induced severe akinesia 
in G2019S KI mice, resulting in a 4-fold increase of immobility time (t=9.58, df=7, 
p<0.001) at 60 min after drug administration. Conversely, haloperidol was ineffective in 
WT mice (t=1.93, df=6, p=0.10; Fig. 14A). In parallel, haloperidol-treated G2019S KI 
mice showed ~75% reduction in the number of steps (t=14.68, df=7, p<0.001; Fig. 20B), 
whereas stepping activity of WT mice was unchanged (t=0.66, df=6, p=0.53; Fig 20B). 
Finally, haloperidol markedly reduced by ~50% rotarod  performance (Fig. 20C) in both 
G2019S KI mice (t=7.6, df=7, p<0.001) and WT mice (t=4.42, df=6; p<0.01). 
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Fig. 20. Effect of systemic injection of haloperidol on motor activity in 11-month-old G2019S KI and WT mice. Motor 
activity was evaluated in the bar (A), drag (B) and rotarod (C) tests at 60 min after haloperidol (0.3 mg/kg, i.p.) 
administration, and expressed as immobility time (sec; A), number of steps (B), and time on rod (sec; C). Data are means 
± SEM of 7 (WT) or 8 (G2019S KI) mice  per group and were analyzed using the Student t-test, two tailed for paired 
data.  *p<0.05, **p<0.01 significantly different from pre-drug. 
 
SCH23390 
SCH23390 was systemically (i.p.) injected in 12-month-old mice (Fig. 21), at  the dose of 
0.01 mg/kg, which was previously found to cause motor impairment in naive mice  (Viaro 
et al., 2013).  SCH23390 increased by ~60% the immobility time in the bar test (Fig. 21A), 
simultaneously reducing by ~35% the number of step in drag test (Fig. 21B) and by ~20% 
the rotarod performance (Fig. 21C) in G2019S KI mice (bar test: genotype F1,13=20.32 
p=0.001, time F2,26=6.40 p=0.005, time x genotype F2,26=11.84 p<0.001; drag test: 
genotype F1,13=12.61 p=0.004, time F2,26 =16.04 p<0.001, time x genotype F2,26=12.60 
p<0.001; rotarod test: genotype F1,13=2.10 p=0.17, time F2,26=2.24 p=0.12, time x genotype 
F2,26=3.34 p=0.051). Conversely, SCH23390 did not cause any significant change of 
immobility time (Fig. 21A), number of steps (Fig. 21B) or rotarod performance (Fig. 21C) 
in WT mice.  
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Fig. 21. Time-course of the motor effects of systemic injection of SCH23390 (0.01 mg/kg, i.p.) in 11-month-old G2019S 
KI mice and wild-type littermates (WT). Motor activity was assessed using the bar (A), the drag (B) and the rotarod tests, 
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before (time 0; basal values) and after (20 and 90 min) drug administration and was expressed as immobility time (sec; 
A), number of steps (B), time on rod (sec; C). Data are means ± SEM of 7 (WT) or 8 (G2019S KI) determinations per 
group and were analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple comparisons. 
*p<0.05, **p<0.01 significantly different from pre-drug (T0). 
 
Pramipexole 
The data collected with DA antagonists would suggest a greater tonic activation of DA 
receptors in G2019S KI mice. To confirm this view, the D2/D3 receptor agonist 
pramipexole (PPX) was tested in 11-month-old mice. In WT mice, PPX reduced the 
immobility time in the bar test (treatment F4,27=15.76 p<0.001; Fig. 22A) at 0.0001 
(∼70%) and 0.001 mg/Kg (∼60%) but was ineffective at higher does (0.01 and 0.1 
mg/Kg), thus showing a bell-shaped curve. In parallel, PPX increased stepping activity in 
the drag test (treatment F4,27=37.83 p<0.001; Fig. 22B) at low doses (0.0001 and 0.001 
mg/kg), being ineffective at higher doses (0.01 and 0.1 mg/Kg). Conversely, in G2019S KI 
mice, PPX was ineffective at low doses (0.0001and 0.001 mg/kg), causing motor inhibition 
at the higher ones (0.01 and 0.1 mg/Kg; bar test: treatment F4,31=24.35 p<0.001, drag test: 
treatment F4,31=51.12 p<0.001; Fig. 22A-B). Finally, PPX reduced rotarod performance at 
0.1 mg/Kg in both genotypes (WT: treatment F4,27=6.37 p=0.001; G2019S KI: treatment 
F4,31=4.55 p=0.005; Fig. 22C).  
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Fig. 22. Effect of systemic injection of pramipexole on motor activity in 11-month-old G2019S KI and WT mice. Motor 
activity was evaluated in the bar (A), drag (B) and rotarod (C) tests at 60 min after pramipexole (0.0001- 0.1 mg/kg, i.p.) 
or saline administration, and expressed as immobility time (sec; A), number of steps (B), and time on rod (sec; C). Data 
are means ± SEM of 7 (WT) or 8 (G2019S KI) mice per group and were analyzed using 1way ANOVA followed by the 
Newman–Keuls test for multiple comparisons. *p<0.05, **p<0.01 significantly different from saline. 
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Relationship between G2019S mutation and DA reuptake in phenotypic mice 
Since experiments in G2019S KI mice suggested that hyperkinetic phenotype is associated 
with a greater saturation of postsynaptic DA receptors, we investigated if DA transporter 
(DAT) function might be dysregulated, thus leading to higher endogenous DA levels.  
 
GBR-12783 
We first investigated DAT function in vivo, using the DAT inhibitor GBR-12783. Motor 
tests were performed in 16-month-old mice at 20 and 60 min after drug administration, at 
two different doses of GBR-12783 (6 and 20 mg/Kg).  
In WT mice, GBR-12783 caused a dose-dependent inhibition of immobility time in the bar 
test at 20 min after administration (Fig. 23A). At later time-point only the higher dose (20 
mg/kg) was effective (time F2,24=27.94 p<0.001, treatment F1,12=4.09 p=0.06, time x 
treatment F2,24=4.05  p=0.031). In the drag test (Fig. 23B), both doses equally improved  
(∼50%) stepping activity, although in this case only the lower one (6 mg/kg; time 
F2,24=33.38 p<0.001, treatment F1,12=1.35 p=0.27, time x treatment F2,24=4.19 p=0.03) 
exerted a long-lasting effect. Finally, GBR-12783 did not alter rotarod performance in WT 
mice (time F2,24=0.79 p=0.47, treatment F1,12=12.18 p=0.004, time x treatment F2,24=2.40  
p=0.11). Different from WT mice, GBR-12783 did not affect motor performance in 
G2019S KI mice at any doses (bar test: time F2,26=0.14 p=0.87, treatment F1,13=0.003 
p=0.96, time x treatment F2,26=1.16 p=0.33; drag test: time F2,26=0.73 p=0.49, treatment 
F1,13=1.57 p=0.23, time x treatment F2,26=0.58 p=0.57; rotarod test: time F2,26=0.44 p=0.65, 
treatment F1,13=8.2 p=0.013, time x treatment F2,26=2.82  p=0.08). 
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Fig. 23. Time-course of the motor effects of systemic injection of GBR-122783 (6 and 20 mg/kg, i.p.) in 16-month-old 
G2019S KI mice and wild-type littermates (WT). Motor activity was assessed using the bar (A), drag (B) and rotarod 
tests, before (time 0; basal values) and after (20 and 90 min) drug administration, and was expressed as immobility time 
(sec; A), number of steps (B), and time on rod (sec; C). Data are means ± SEM of 9-10 (6 mg/kg) or 5 (20 mg/kg) mice 
per group and were analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple comparisons. 
*p<0.05, ** p<0.01 significantly different from pre-drug (T0). 
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GBR-12783 and Nov-LRRK2-11 
The insensitivity of G2019S KI mice to GBR-12783, led us to suppose that DAT was 
dysfunctional in these mice. As we previously observed that blocking LRRK2 kinase 
activity with Nov-LRRK2-11 worsened motor activity in G2019S mice, we investigated 
the cross-talk between the G2019S LRRK2 mutation and DAT-mediated motor behavior.  
To this purpose, 16-month-old mice were divided into three different experimental groups. 
One group was systemically injected with vehicle, while the other two with Nov-LRRK2-
11 (i.p. 10 mg/kg). Mice treated with Nov-LRRK2-11 were further allotted into two groups 
and injected (15 min later) either with GBR-12783 (i.p. 20 mg/kg) or vehicle (i.p.).  
As expected, Nov-LRRK2-11 increased the immobility time (∼2-fold; time F3,51=23.73 
p<0.001, treatment F2,17 =30.30  p<0.001, time x treatment F6,51=27.89  p<0.001; Fig. 24A) 
and reduced the number of step (∼2-fold; time F3,51=30.75 p<0.001, treatment F2,17=23.80  
p<0.001, time x treatment F6,51=14.99 p<0.001; Fig.24B) in G2019S KI mice. 
Interestingly, these effects were reversed by GBR-12783 in both tests (Fig. 24).  
 
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
0
5
10
15
20
25
30
35
40
45
50
time (min)
A
Nov-LRRK2-11 + vehicle
Nov-LRRK2-11 10 mg/kg + GBR-12783 20 mg/kg
No v -LRRK 2 -1 1
GBR-1 2 7 8 3
*
**
°°
**
°°
## ##
Vehicle
Im
m
o
b
il
it
y 
ti
m
e
 (
se
c)
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
0
2
4
6
8
10
12
14
16
18
20
22
time (min)
B
No v -LRRK 2 -1 1
GBR-1 2 7 8 3
**
##
##
**
°°**
°°
Nov-LRRK2-11 + vehicle
Nov-LRRK2-11 + GBR-12783
Vehicle
N
u
m
b
e
r 
o
f 
st
e
p
s
 
Fig. 24. Time-course of the motor effects of systemic injection of Nov-LRRK2-11 (10 mg/Kg i.p.) and GBR-12783 (20 
mg/Kg i.p.) in 16-month-old G2019S KI mice. Motor activity was assessed using the bar (A) and drag (B) tests, before 
(time 0; basal values) and after (15, 35, 75 min) drug administration, and was expressed as immobility time (sec; A) and 
number of steps (B). Data are means ± SEM of 6 (vehicle) or 7 (Nov-LRRK2-11; Nov-LRRK2-11 + GBR-12783) mice 
per group and were analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple comparisons. 
*p<0.05, **p<0.01 significantly different from pre-drug (T0). ##p<0.01 significantly different from the 15 min time-
point; °°p<0.01 significantly different from Nov-LRRK2-11 + GBR-12783 at the same time-point. 
 
 
 
70 
 
Analysis on DAT and VMAT2 protein levels  
Overall, these data suggest that the G2019S mutation affects DA reuptake in G2019S KI 
mice, possibly through  changes of DAT activity and/or expression.  
To investigate whether the G2019S mutation alters DAT (and VMAT2) protein expression 
we assessed DAT protein levels with western blot in ex-vivo striatal samples from 12-
month-old G2019S KI and WT mice. G2019S KI mice showed lower protein DAT levels 
(∼50%; Fig. 25) compared to WT mice. Similarly, lower levels of total endogenous 
VMAT2 were detected  in G2019S KI mice (∼60%; Fig. 25).  
 
Fig. 25. Expression of DAT (A) and VMAT2 (B) in striatum of 12-month-old G2019S KI mice and WT littermates. Data 
are means ± SEM of 3 mice per genotype, and were analyzed using the Student t-test two-tailed for unpaired data. 
*P<0.05 different from WT. 
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Membrane DAT expression and function 
The reduction in DAT protein levels led us to investigated if any change of DAT 
expression at the presynaptic membrane occurred in G2019S mice. To this purpose, 
saturation binding experiments in striatal synaptosomes of 7-month-old G2019S KI and 
WT mice were performed using [
3
H]-WIN 35,428 as DAT ligand. Data revealed no 
significant difference in DAT density between G2019S KI and WT mice, according to the 
similar Bmax values measured in G2019S KI mice (5.77 ± 0.10 pmol/mg protein) and WT 
mice (5.46 ± 0.25 pmol/mg protein; Fig. 26A). The affinity of [3H]-WIN 35,428 for DAT 
was also similar in striatal synaptosomes from G2019S KI and WT mice, with KD values 
of 9.08 ± 0.23 nM and 8.93 ± 0.70 nM, respectively.  
Since no differences in DAT density were found between genotypes, kinetic analysis of 
DA uptake was performed. A significant 60% increase of maximal transport rate (Vmax) in 
striatal synaptosomes from G2019S KI with respect to WT mice was found (P<0.01, Fig. 
26B). No significant differences were observed in Km values, a measure of DA affinity for 
the transporter. 
 
  
 
 
 
 
 
 
Fig. 26. Expression and function of DAT in striatal synaptosomes of LRRK2 G2019S KI (KI) and WT mice. Dopamine 
transporter density expressed as Bmax values obtained from [3H]-WIN 35,428 saturation binding experiments in 
synaptosomes from KI and WT mice (A). Kinetic analysis of [3H] Dopamine (DA) uptake in synaptosomes from KI and 
WT mice (B). Values are expressed as mean ± SEM of 3 independent experiments performed in duplicate. *P<0.01 vs 
WT. 
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In vivo microdialysis  
Since data from behavioral pharmacology studies together with ex-vivo/in vitro 
experiments are consistent with the view that G2019S KI mice exhibit an altered 
dopaminergic tone likely associated with dysregulation of DA reuptake, we used 
microdialysis to measure extracellular levels of DA and DA metabolites in dorsal striatum 
of 19-month-old mice G2019S KI and WT mice (Figs. 27-28).  
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Fig. 27. Basal levels (nM) of DA (A), DOPAC (B), 3MT (C) and HVA (D) from dorsal striatum of 19-month-old 
G2019S knock-in (G2019S KI) and wild-type littermates (WT) mice. In vivo microdialysis shows similar striatal levels 
of DA and its metabolites (DOPAC, 3MT and HVA) in both G2019S KI  and WT mice. Data are means ± SEM of 11-15 
determinations per group and were analyzed using the Student t test, two-tailed for paired data. 
 
No significant difference was detected between levels of DA and DA metabolites in 
G2019S KI (t=0.78, df=24, p=0.43) and WT mice (Fig. 27). Interestingly, however, 
G2019S KI mice showed significant lower metabolite/DA ratio (DOPAC/DA: t=2.17, 
df=17, p=0.043; 3MT/DA: t=2.26, df=11, p=0.04; HVA/DA: t=2.43, df=21, p=0.023; Fig. 
28) with respect to WT mice. 
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Fig 28. Ratios between basal levels of DOPAC and DA (A), 3MT and DA (B), HVAand DA (C)as obtained from 
microdialysis in the dorsolateral striatum of G2019S knock-in (G2019S KI) and wild-type littermates (WT) mice. Data 
are means ± SEM of 10 (WT) or 13 (G2019S KI) determinations per group and were analyzed using the Student t test, 
two-tailed for paired data. *P<0.05 different from WT.  
 
To test the responsiveness of striatal DA levels to DAT blockade, GBR-12783 was given. 
In the striatum of WT mice DA levels transiently rose after GBR-12783 challenge, peaking 
(∼ 4-fold over basal) at 40 min (Fig. 29) after administration (time F6,78=13,62 p<0.001, 
time x genotype F6,78=3.45 p=0.005, genotype F1,13=0.15 p=0.707). G2019S KI mice 
showed a shallow and slow in onset increase in DA levels after GBR-12783 
administration, with maximal levels (0.57 ± 0.084 nM) reached at 60 min (Fig. 29).  
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Fig. 29. Neurochemical effects on dorsolateral striatal basal level of DA after systemic injection of GBR-12783 (20 
mg/kg, i.p.) in 19-month-old G2019S knock-in (G2019S KI) and wild-type littermates (WT) mice undergoing 
microdialysis. Basal dialysate levels of DA are expressed as absolute levels (nM) and are mean ± SEM of 6 (WT) or 9 
(G2019S KI) animals. Statistical analysis was performed using one-way RM ANOVA followed by the Newman–Keuls’s 
test for multiple comparisons. * p<0.05; ** p<0.01 significantly different from T0 per each genotype 
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Finally, Nov-LRRK2-11 (i.p.; 10 mg/kg) was injected 48 h after surgery and  no 
differences in DA levels were detected between genotypes (time F7,49=0,85 p=0.55, time x 
genotype F7,49=0.86 p=0.54, genotype F1,7=1.33 p=0.29; Fig. 30). 
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 Fig. 30. Neurochemical effects on dorsolateral striatal basal level of DA after systemic injection of Nov-LRRK2-11 (10 
mg/kg, i.p.) in 19-month-old G2019S knock-in (G2019S KI) and wild-type (WT) mice undergoing microdialysis. Basal 
dialysate levels of DA are expressed as absolute values (nM), and are mean ± SEM of 5 (WT) or 6 (G2019S KI) animals.  
 
Nigrostriatal DA system  
Stereological techniques and TH-immunostaining were used to analyze the number of DA 
cells in SNpc as well as the dopaminergic innervation in the striatum of 19-month-old 
G2019S KI and WT littermates. No differences were found in striatal dopaminergic 
density (Fig. 30 and Fig. 31A) or in the total number of nigral dopaminergic neurons (Fig. 
31B) between genotypes.  
 
Fig. 30. Immunofluorescence images showing TH positive terminals in the striatum of WT (A) and G2019S KI (B) mice. 
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Fig. 31. TH immunoreactivity quantification (A) and sterological count of nigral DA neurons (B) in G2019S KI and WT 
mice (B). Data are expressed as absolute values and represent optical density (A) and number of positive neurons (B) and 
are means ± SEM of 6 determination per group. Statistical analysis was performed with the Student’s t test, two tailed for 
unpaired data. 
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Previous studies have attempted to replicate a parkinsonian-like phenotype in rodents by 
overexpressing pathogenic G2019S LRRK2 mutation. These studies differ in many ways, 
such as the technology used (BAC or cDNA trangenesis, viral vectors), the levels of 
transgene expression and its neuronal localization, the mouse strain and, not last, the motor 
tests used. Nonetheless, these studies failed in showing a detrimental effect of G2019S on 
motor functions, unless high levels of transgene expression are artificially attained in 
substantia nigra neurons via the CMV/PDGF promoter, leading to 30–50% neuronal loss 
(Chen et al., 2012). Consistent with this view, no motor change was observed in another 
study on these mice (although bred on a different background), where a lower level of 
transgene expression in DA neurons and, consequently, a lower degree of substantia nigra 
neurodegeneration was achieved (18%) (Ramonet et al., 2011). To extend previous studies, 
here we provide the results of the first longitudinal phenotyping study in G2019S KI mice, 
showing that expression of mouse LRRK2 gene carrying the G2019S mutation confers a 
hyperkinetic phenotype, that is resistant to age-related motor decline. The robust and long 
lasting hyperkinetic phenotype described was substantially confirmed by a transversal 
motor analysis of different age-matched cohorts of G2019S KI and WT mice. Two lines of 
evidence seem to confirm that enhancement of kinase activity, which is a consequence of 
the G2019S mutation (Greggio et al., 2006; Jaleel et al., 2007; West et al., 2005), is 
somehow responsible for the increase in motor performance: i) the motor function of mice 
carrying a kinase-silencing mutation (D1994S) showed normal age-related motor 
worsening superimposable to that of WT littermates and ii) ATP-competitive kinase 
inhibitors reversed the hyperkinetic phenotype selectively in G2019S KI mice. Further 
evidence that enhancement of LRRK2 kinase activity might be responsible for the 
observed motor phenotype in G2019S KI mice comes from KI mice carrying the R1441C 
mutation in the ROC domain (Xiong et al., 2012). In fact, the R1441C mutation induces a 
milder increase of kinase activity with respect to the G2019S mutation  (West et al., 2005), 
or no increase at all (Jaleel et al., 2007), and motor activity of R1441C KI mice in the open 
field and rotarod appears to be unchanged up to 24 months of age (Tong et al., 2009). The 
motor phenotype described in the present study clearly differs from that reported in 
G2019S overexpressing mice, although transient and test-related motor facilitation has 
been observed in those mice. For instance, BAC mice overexpressing human G2019S 
LRRK2 showed faster walking speed (and anxiety-like behavior) in the open field 
(Melrose et al., 2010) whereas human G2019S overexpressors under the Thy1 (Herzig et 
al., 2011) or the TetO CaMKII (Lin et al., 2009) promoters showed transient improvement 
in rotarod performance (Herzig et al., 2011) or increased exploratory behavior (Lin et al., 
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2009). In addition, rats temporarily, but not constitutively, overexpressing human G2019S 
LRRK2 showed increased exploratory behavior in the open field at 18 months (Zhou et al., 
2011). The influence of G2019S LRRK2 on motor function was evident in tests specific 
for akinesia/bradykinesia (bar and drag tests), and spontaneous exploratory behavior (open 
field), but not in a test for exercise driven motor activity (rotarod). This might suggest an 
influence of G2019S LRRK2 on specific motor parameters. Indeed, stepping activity 
involves striatal sensory–motor function (Kirik et al., 1998) whereas the rotarod test 
integrates both motor and non-motor (e.g. motivation to run) functions, and likely involves 
multiple brain areas (e.g. basal ganglia and cerebellum),where LRRK2 is expressed to a 
different degree (Higashi et al., 2007; Melrose et al., 2007). However, both in the bar and 
drag test, the main effect of G2019S was to preserve motor function from aging, 
suggesting that, more in general, G2019S mutation might confer a phenotype which is 
more resistant (or less sensitive) to the age-related motor decline. The possibility that this 
hyperkinetic phenotype is associated with changes of neurotransmitter release should be 
considered. Indeed, both LRRK2 silencing (Piccoli et al., 2011) or expression of the 
G2019S mutation (Migheli et al., 2013) has been reported to facilitate exocytosis, 
consistent with the finding that too much or too little kinase activity has a negative impact 
on vesicle trafficking (Matta et al., 2012). Consistently, pharmacological inhibition of 
LRRK2 activity impairs vesicle endocytosis and neurotransmitter release (Cirnaru et al., 
2014). Moreover, enhancement of the stimulus-induced DA release has been detected in 
PC12 cells expressing the G2019S mutation (Migheli et al., 2013). Therefore, we might 
hypothesize that the hyperkinetic phenotype of G2019S KI mice is due to increased DA 
concentration at the synaptic cleft. Alternatively, an increased motor activity could result, 
even in the absence of an elevation of DA levels, from an increased expression of 
postsynaptic D1 receptors, as suggested by study in G2019S expressing cells (Migheli et 
al., 2013). The motor phenotype of G2019S KI mice seems to be achieved through a gain-
of-function process. Indeed, silencing kinase activity does not affect motor function. The 
lack of endogenous control over motor activity by endogenous LRRK2 is further supported 
by the absence of a clear motor phenotype in LRRK2 knockout mice (Herzig et al., 2011; 
Lin et al., 2009), although exploratory changes consistent with anxiety-like behavior, and 
(transient) facilitation of rotarod performance have also been reported in these mice 
(Hinkle et al., 2012).While our results disclose robust motor alterations in G2019S KI 
mice, KI mice expressing other pathological LRRK2 mutations as well as G2019S KI mice 
from other laboratories need to be assessed in these motor tests to strengthen the 
involvement of LRRK2 kinase activity in this paradigm. Interestingly, mice carrying PD-
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linked mutations, such as α-synuclein overexpressed under the Thy1 promoter (Lam et al., 
2011), or parkin and DJ-1 double knock-out mice (Hennis et al., 2014) were found to be 
hyperactive and have increased striatal DA levels in their pre-symptomatic phase, possibly 
indicating compensatory mechanisms preceding nigro-striatal DA system demise. Whether 
the hyperactive motor phenotype of G2019S KI mice might be considered as the result of 
pre-symptomatic compensatory changes is presently under investigation. To possibly 
support this view, asymptomatic human G2019S carriers have higher putaminal DA 
turnover rate (Sossi et al., 2010). The fact that we did not observe a reversal of motor 
hyperactivity into frank hypokinesia, as in α-synuclein overexpressors (Lam et al., 2011), 
up to 19 months, might indicate a longer and slower pre-symptomatic phase in G2019S KI 
mice, in line with the different ages at onset of the disease, i.e. juvenile for α-synuclein 
related PD, and late for G2019S related PD (Hardy et al., 2009). To date, the requirement 
of kinase activity in LRRK2 pathogenic effects is still unclear. For instance, there is also 
growing evidence that the LRRK2 levels are driving the neuropathology rather than the 
kinase activity (Herzig et al., 2011; Skibinski et al., 2014). Nevertheless, the influence of 
LRRK2 on motor function and on neurotoxicity can procede through two independent 
mechanisms. Another important finding of the present study is the demonstration that 
ATP-competitive LRRK2 kinase inhibitors reversed the motor phenotype in G2019S KI 
mice. Both H-1152 and Nov-LRRK2-11 were able to inhibit LRRK2 kinase activity and 
reduce LRRK2 phosphorylation at Ser935 in NIH3T3 cells. This confirms previous 
findings that LRRK2 kinase inhibition with H-1152 abolishes binding to 14-3-3 proteins, 
resulting in de-phosphorylation of LRRK2 at Ser910 and Ser935 (Dzamko et al., 2010). 
Based on these data, phosphorylation at Ser935 has been proposed as a readout of LRRK2 
kinase activity (Dzamko et al., 2010) although this phosphorylation is not the direct 
consequence of autophosphorylation but is possibly controlled by a LRRK2-activated 
kinase/phosphatase and, therefore, does not always correlate with kinase activity (Dzamko 
et al., 2010). In our hands, Nov-LRRK2-11 reversed the phenotype of G2019S KI mice 
and inhibited LRRK2 phosphorylation at 10 mg/kg, confirming ex vivo pulldown 
experiments showing that Nov-LRRK2-11 penetrates into the brain (Troxler et al., 2013). 
Behavioral data were in agreement with PK data after 3 mg/kg oral dose, and with the 
apparent terminal half-life of Nov-LRRK2-11 in blood after i.v. dosing of 1 mg/kg (0.4 h) 
(Herzig et al., 2011; Troxler et al., 2013). Interestingly, the same behavioral effect was 
observed at ten-fold lower doses of H-1152, suggesting significant brain penetration also 
for H-1152, for which, however, no published pharmacokinetic are available. Further 
validation of this motor reversal phenotype with additional compounds inhibiting LRRK2 
80 
 
is of course desirable and necessary. The present study shows a clear dissociation between 
motor changes and in vivo LRRK2 phosphorylation. Indeed, Nov-LRRK2-11 inhibited 
motor activity in G2019S KI mice causing only minimal effects (on rotarod performance) 
in WT mice, in face of a marked inhibition of LRRK2 phosphorylation in the striatum and 
cerebral cortex of both genotypes. Moreover, although H-1152 consistently inhibited motor 
activity and LRRK2 phosphorylation in G2019S KI but not WT mice, its motor effects far 
exceeded those on LRRK2 phosphorylation. The most parsimonious way to explain this 
discrepancy is that LRRK2 de-phosphorylation at Ser935 is a marker for in vivo target 
engagement of LRRK2 kinase inhibitors, but does not follow their motor effects. Perhaps, 
other phosphorylation, or autophosphorylation (Sheng et al., 2012), site(s) on LRRK2 
should be monitored. In fact, we should recall that both inhibitors target other kinases 
beyond LRRK2, which may act upstream and downstream of LRRK2. For instance, PKA 
has been shown to crosstalk with LRRK2 (Li et al., 2011; Muda et al., 2014; Parisiadou et 
al., 2014), whereas ROCK/MLCK are involved in actin cytoskeleton remodeling pathways, 
in which activity they could crosstalk with LRRK2. On the other hand, given the parallel 
(albeit temporally-dissociated) inhibition of motor activity and striatal LRRK2 
phosphorylation induced by H-1152, we might speculate that striatal LRRK2 is a key 
regulator of motor activity. In this case, if higher LRRK2 kinase activity is present in the 
striatum of G2019S KI mice compared to WT mice, as predicted, normalization of these 
levels by LRRK2 kinase inhibitors might represent the trigger of a cascade of events 
leading to sustained motor inhibition. Moreover, the different patterns of LRRK2 de-
phosphorylation of Nov-LRRK2-11 and H-1152 in G2019S KI and WT mice suggest a 
higher LRRK2 selectivity and/or brain exposure/free fraction of Nov-LRRK2-11. For 
further confirmation, additional information on earlier times-points (< 20 min) of Nov-
LRRK2-11 effects as well as higher doses of H-1152 would be desirable. In addition, the 
finding that Nov-LRRK2-11 reduces LRRK2 levels in the cortex but not striatum indicates 
different properties of the LRRK2 system in these two areas.  
The identification of a hyperkinetic phenotype in G2019S KI mice, causally linked to an 
increase of LRRK2 kinase activity, led us to investigate the underlying biochemical and 
neurochemical dopaminergic mechanisms. It is known that there is a preclinical stage in 
which patients with familial PD are asymptomatic, despite alterations of DA homeostasis 
start emerging  (Adams et al., 2005; Nandhagopal et al., 2008; Sossi et al., 2010). We 
therefore attempted to unravel a relationship between dysregulation of motor activity and 
dopaminergic transmission in G2019S KI mice. Dopaminergic transmission comprises DA 
synthesis, the packaging of DA into synaptic vesicles by VMAT2, the release of DA into 
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the synaptic cleft, the interaction of DA with presynaptic and postsynaptic DA receptors, 
the reuptake of DA into presynaptic DA nerve terminals via the plasma membrane DAT, 
and the degradation of intra/extracellular DA by monoamine oxidases (MAO) and 
catechol-O-methyltransferases (COMT) .  
We first analyzed the responsiveness to dopaminergic drugs, in behavioral pharmacology 
experiments. The cataleptic response to haloperidol observed in G2019S KI but not WT 
mice suggests dysregulation of DA transmission at striato-pallidal MSNs. In fact, a 
negative interaction between D2 and A2A receptors on PKA activity and cAMP level 
production occurs in striato-pallidal MSNs (Ferre et al., 1994; Ferre et al., 1991). Thus, a 
greater cataleptic response might correlate with greater activity at A2A receptors. In fact, 
blockade of postsynaptic D2 receptors on striato-pallidal MSNs favors the action of A2A 
receptors (Tozzi et al., 2011). A greater activity at A2A receptors, in turn, might reflect 
greater Golf levels, since striatal A2A receptors are coupled to Golf (Hervè, 2011). The 
possibility of a greater signaling through Golf is also corroborated by the finding that the 
blockade of D1/D5 receptors, which signal through Golf, with SCH23390 worsens  motor 
performance in G2019S KI mice but not WT controls.  
In favor of an increased DA signaling, expression of G2019S LRRK2 in PC12 cells causes 
an increase in D1 receptor expression at cell membrane, possibly due to the LRRK2 
interference with receptor turnover and endocytosis (Migheli et al., 2013). In addition, 
since LRRK2 interacts with PKARII regulatory subunit (Parisiadou et al., 2014), which is 
abundant in striatal MSNs, changes in responsiveness of MSNs to DA might occur in 
G2019S KI mice, as demonstrated for R1441C KI mice (Parisiadou et al., 2014).  
The different responsitivity of G2019S KI and WT mice to DA receptor selective 
antagonists, however, might also have a presynaptic origin,  and be due to greater DA 
release and tonic activation (saturation) of DA receptors. We therefore investigated the 
behavioral outcome of D2 receptor activation. The D3/D2 receptor agonist PPX facilitated 
movement at low doses but was ineffective at higher ones in WT mice, providing a bell-
shaped curve. Conversely, PPX was ineffective at low doses and inhibited motor function 
at higher ones, in G2019S KI mice. Motor impairment induced by DA agonists is known to 
be mediated by presynaptic D2/D3 autoreceptors (Maj et al., 1997; Mierau and Schingnitz, 
1992; Siuciak and Fujiwara, 2004). Indeed, motor inhibition is the predominant action of 
D2 agonists in mice having intact DA transmission. Conversely, D2-mediated facilitation 
emerges in conditions where DA is reduced and D2 postsynaptic receptors upregulated, as 
in PD (Seeman, 2007). Considering that in WT mice DA transmission might be 
dysregulated do to the aging process, we speculate that low doses of PPX act on up-
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regulated D2 postsynaptic receptors to promote movement whereas high doses of PPX 
recruit D2 presynaptic receptors, thus reversing motor facilitation. Conversely, in G2019S 
KI mice, PPX provided monophasic motor inhibition, likely acting on presynaptic D2 
(auto)receptors. This indicates that, different from WT mice, DA transmission is intact and 
D2 postsynaptic receptors saturated in G2019S KI mice. In keeping with this view, no 
changes in striatal dopaminergic innervation or nigral DA cell number were found between 
genotypes. Moreover, microdialysis revealed no difference in extracellular DA levels 
between genotypes, suggesting that the hyperkinetic phenotype of G2019S mice does not 
rely on alterations of DA neuron activity. Indeed, previous microdialysis studies revealed 
that basal striatal extracellular DA levels reflect neuronal activity (for reviews see(Kehr, 
1993; Westerink, 1995). Consistently, administration of a dose of Nov-LRRK2-11 that 
reduced motor activity did not affect striatal DA release. In light of these data, we can 
speculate that motor inhibition induced by Nov-LRRK2-11 is DA-independent and might 
occur either presynaptically, through inhibition of LRRK2 kinase activity regulating 
exocytosis at non-DA nerve terminals, or postsynaptically, through inhibition of LRRK2 
kinase activity regulating DA signaling at MSNs.  
Despite enhanced DA levels were not associated with the hyperkinetic phenotype of 
G2019S mice, signs of dysregulated presynaptic DA release machinery were evident in 
this genotype.  First, G2019S KI mice showed a significantly lower metabolite/DA ratio, 
suggesting reduced DA turnover. It appears worth investigating, in future experiments, the 
enzymatic activity of COMT and/or MAO. Moreover, and perhaps more relevant, 
dysfunction of DAT was found in G2019S KI mice. Indeed, the DAT inhibitor GBR-
12783 induced motor facilitation in WT mice, as expected, but was ineffective in G2019S 
KI mice. This lack of behavioral response might be due to the greater saturation of 
postsynaptic DA receptors, insensitive to further increases in DA levels, or be directly 
related to altered DAT function/expression. In favor of the latter, in vivo microdialysis 
showed a blunted DA response to acute DAT blockade with GBR-12783 in G2019S KI 
mice. Moreover, despite no difference in maximal WIN-35,428 binding to DAT was found 
between genotypes, reduced DAT protein levels and greater maximal transport rate (Vmax) 
were found in G2019S mice. Increase in Vmax might represent an attempt to compensate for 
the lower intracellular expression of DAT, suggesting a probable adaptation process within 
the presynaptic molecular machinery.  
Of note, DAT function and trafficking are modulated by D2 autoreceptors  via Gi/Go-
dependent manner and require ERK1/2 activation. In particular, DAT is regulated by D2 
autoreceptors through a direct physical interaction, and disruption of this  interaction in the 
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mouse brain in vivo results in decreased striatal synaptosomal DA uptake and increased 
locomotor activity. On the other hand, DAT regulation is DA-dependent and is modulated 
by numerous signal transduction mechanisms, including a palette of protein kinases such 
as Ca
2+
/calmodulin-dependent protein kinase II (CaMKII) and PKC. Numerous studies 
have demonstrated that direct activation of PKC leads to downregulation of DAT activity 
with an accompanying redistribution of DAT from the membrane. Likewise, there is some 
evidence that PKC may mediate DAT substrate-stimulated downregulation of DAT 
activity (Chen et al., 2010). In addition, increase of surface DAT expression is dependent 
on soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
proteins such as syntaxin 1A and the vesicle-associated membrane protein 
(VAMP)/synaptobrevin which participate in the process of membrane fusion and 
exocytosis (Furman et al., 2009). Moreover, since DA release at the nerve terminal is 
mediated by the SNARE complex-dependent fusion of SVs, and is triggered by Ca
2+
 
binding to synaptotagmins, we are tempting to speculate that G2019S LRRK2 might affect 
presynaptic machinery at different levels, modulating DAT trafficking/function by 
interacting with different kinases (i.e. ERK) and /or mobilizing SVs by acting on syntaxin 
1A via its kinase activity.  
To support the cross-talk between G2019S LRRK2 and DAT-mediated motor behavior, we 
show that the impaired motor behavior caused by blockade of LRRK2 kinase activity with 
Nov-LRRK2-11 was reversed upon GBR-12783 administration To possibly reinforce this 
view, the inducible temporal expression of G2019S LRRK2 in adult rats was associated 
with an increase of extracellular DA levels and a consequent enhancement of locomotor 
activity through gradual damage to DAT-mediated DA reuptake (Zhou et al., 2011). 
Supporting clinical evidence obtained by in vivo PET (positron emission tomographic) 
scanning in mutant LRRK2 carriers at asymptomatic stages reveals reduced DAT and 
VMAT2 binding even in the absence of clinically evident parkinsonism (Adams et al., 
2005; Nandhagopal et al., 2008).  
 
Concluding remarks 
The present longitudinal phenotypic study provides genetic evidence that expression of the 
G2019S mutation under the endogenous promoter confers mice with better motor 
performances and preserves their age-related motor decline in tests specific for 
akinesia/bradykinesia. Enhancement of LRRK2 kinase activity likely underlies this 
phenotype since D1994S KD mice do not display motor abnormalities, and ATP-
competitive LRRK2 inhibitors reversed motor phenotype in G2019S KI mice.  
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In particular, a correlation between in vivo motor effects of LRRK2 inhibitors and their 
ability to de-phosphorylate LRRK2 at Ser935 was shown for the first time. For these 
reasons, the present thesis work proposes G2019S KI mice as a valuable in vivo model to 
investigate the effects of LRRK2 inhibitors. 
Moreover, we pointed out a correlation between hyperkinetic phenotype and an altered 
dopaminergic transmission, even though no changes in nigral DA cell counts or 
dopaminergic striatal nerve terminal density were observed in G2019S KI mice. However, 
the overall pattern of responses to a D2/D3 receptor agonist or antagonists, and to D1/D5 
receptor antagonist suggested an elevated tonic activation of DA receptors in G2019S KI 
mice. Moreover, a cross-talk between the G2019S LRRK2 mutation and DAT-mediated 
motor behavior was unraveled, suggesting that G2019S LRRK2 might affect presynaptic 
dopaminergic machinery.  
This study challenges the idea that G2019S is detrimental for motor activity in rodents, 
suggesting that other factors might be involved in inducing a PD-like phenotype, such 
alpha-synuclein (for reviews see (Greggio et al., 2011; Taymans and Cookson, 2010), or 
parkin (Smith et al., 2005).  
Nonetheless, in G2019S KI mice, the reduced DA turnover together with loss of synaptic 
VMAT2, might result in accumulation of DA within the synapse, making it available to 
oxidation and leading to the formation of reactive byproducts (es DOPAL) which 
ultimately might damage dopaminergic neurites (Bisaglia et al., 2013; Marchitti et al., 
2007). 
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